The	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	I-Disease
APC	I-Disease
)	I-Disease
tumour	I-Disease
-	O
suppressor	O
protein	O
controls	O
the	O
Wnt	O
signalling	O
pathway	O
by	O
forming	O
a	O
complex	O
with	O
glycogen	O
synthase	O
kinase	O
3beta	O
(	O
GSK	O
-	O
3beta	O
)	O
,	O
axin	O
/	O
conductin	O
and	O
betacatenin	O
.	O

Like	O
APC	O
,	O
APC2	O
regulates	O
the	O
formation	O
of	O
active	O
betacatenin	O
-	O
Tcf	O
complexes	O
,	O
as	O
demonstrated	O
using	O
transient	O
transcriptional	O
activation	O
assays	O
in	O
APC	O
-	O
/	O
-	O
colon	B-Disease
carcinoma	I-Disease
cells	O
.	O

A	O
common	O
MSH2	O
mutation	O
in	O
English	O
and	O
North	O
American	O
HNPCC	B-Disease
families	O
:	O
origin	O
,	O
phenotypic	O
expression	O
,	O
and	O
sex	O
specific	O
differences	O
in	O
colorectal	B-Disease
cancer	I-Disease
.	O

Although	O
this	O
mutation	O
was	O
initially	O
detected	O
in	O
four	O
of	O
33	O
colorectal	B-Disease
cancer	I-Disease
families	O
analysed	O
from	O
eastern	O
England	O
,	O
more	O
extensive	O
analysis	O
has	O
reduced	O
the	O
frequency	O
to	O
four	O
of	O
52	O
(	O
8	O
%	O
)	O
English	O
HNPCC	B-Disease
kindreds	O
analysed	O
.	O

To	O
investigate	O
the	O
origin	O
of	O
this	O
mutation	O
in	O
colorectal	B-Disease
cancer	I-Disease
families	O
from	O
England	O
(	O
n	O
=	O
4	O
)	O
,	O
Newfoundland	O
(	O
n	O
=	O
10	O
)	O
,	O
and	O
the	O
United	O
States	O
(	O
n	O
=	O
3	O
)	O
,	O
haplotype	O
analysis	O
using	O
microsatellite	O
markers	O
linked	O
to	O
MSH2	O
was	O
performed	O
.	O

We	O
calculated	O
age	O
related	O
risks	O
of	O
all	O
,	O
colorectal	B-Disease
,	I-Disease
endometrial	I-Disease
,	I-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
in	O
nt943	O
+	O
3	O
A	O
-	O
-	O
>	O
T	O
MSH2	O
mutation	O
carriers	O
(	O
n	O
=	O
76	O
)	O
for	O
all	O
patients	O
and	O
for	O
men	O
and	O
women	O
separately	O
.	O

The	O
risk	O
of	O
colorectal	B-Disease
cancer	I-Disease
was	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
males	O
than	O
females	O
(	O
0	O
.	O
63	O
v	O
0	O
.	O
30	O
and	O
0	O
.	O
84	O
v	O
0	O
.	O
44	O
at	O
ages	O
50	O
and	O
60	O
years	O
,	O
respectively	O
)	O
.	O

These	O
intersex	O
differences	O
in	O
colorectal	B-Disease
cancer	I-Disease
risks	O
have	O
implications	O
for	O
screening	O
programmes	O
and	O
for	O
attempts	O
to	O
identify	O
colorectal	B-Disease
cancer	I-Disease
susceptibility	O
modifiers	O
.	O

Age	O
of	O
onset	O
(	O
AO	O
)	O
of	O
Huntington	B-Disease
disease	I-Disease
(	O
HD	B-Disease
)	O
is	O
known	O
to	O
be	O
correlated	O
with	O
the	O
length	O
of	O
an	O
expanded	O
CAG	O
repeat	O
in	O
the	O
HD	B-Disease
gene	O
.	O

We	O
therefore	O
determined	O
APOE	O
genotype	O
and	O
normal	O
CAG	O
repeat	O
length	O
in	O
the	O
HD	B-Disease
gene	O
for	O
138	O
HD	B-Disease
patients	O
who	O
were	O
previously	O
analysed	O
with	O
respect	O
to	O
CAG	O
repeat	O
length	O
.	O

Our	O
findings	O
suggest	O
that	O
subtle	O
differences	O
in	O
the	O
course	O
of	O
the	O
neurodegeneration	B-Disease
in	O
HD	B-Disease
may	O
allow	O
interacting	O
genes	O
to	O
exert	O
gender	O
specific	O
effects	O
upon	O
AO	O
.	O

The	O
serum	O
of	O
a	O
29	O
-	O
year	O
old	O
woman	O
with	O
a	O
recent	O
episode	O
of	O
disseminated	B-Disease
gonococcal	I-Disease
infection	I-Disease
and	O
a	O
history	O
of	O
meningococcal	B-Disease
meningitis	I-Disease
and	O
arthritis	B-Disease
as	O
a	O
child	O
was	O
found	O
to	O
lack	O
serum	O
hemolytic	O
complement	O
activity	O
.	O

Complete	B-Disease
absence	I-Disease
of	I-Disease
C7	I-Disease
was	O
also	O
found	O
in	O
one	O
sibling	O
who	O
had	O
the	O
clinical	O
syndrome	O
of	O
meningococcal	B-Disease
meningitis	I-Disease
and	O
arthritis	B-Disease
as	O
a	O
child	O
and	O
in	O
this	O
siblings	O
clinically	O
well	O
eight	O
-	O
year	O
-	O
old	O
son	O
.	O

This	O
report	O
represents	O
the	O
first	O
cases	O
of	O
C7	B-Disease
deficiency	I-Disease
associated	O
with	O
infectious	O
complications	O
and	O
suggests	O
that	O
bactericidal	O
activity	O
may	O
be	O
important	O
in	O
host	O
defense	O
against	O
bacteremic	B-Disease
neisseria	I-Disease
infections	I-Disease
.	O

OBJECTIVE	O
Previous	O
reports	O
have	O
suggested	O
an	O
increased	O
risk	O
of	O
cancer	B-Disease
among	O
patients	O
with	O
cartilage	B-Disease
-	I-Disease
hair	I-Disease
hypoplasia	I-Disease
(	O
CHH	B-Disease
)	O
.	O

STUDY	O
DESIGN	O
One	O
hundred	O
twenty	O
-	O
two	O
patients	O
with	O
CHH	B-Disease
were	O
identified	O
through	O
2	O
countrywide	O
epidemiologic	O
surveys	O
in	O
1974	O
and	O
in	O
1986	O
.	O

RESULTS	O
A	O
statistically	O
significant	O
excess	O
risk	O
of	O
cancer	B-Disease
was	O
seen	O
among	O
the	O
patients	O
with	O
CHH	B-Disease
(	O
standardized	O
incidence	O
ratio	O
6	O
.	O
9	O
,	O
95	O
%	O
confidence	O
interval	O
2	O
.	O
3	O
to	O
16	O
)	O
,	O
which	O
was	O
mainly	O
attributable	O
to	O
non	B-Disease
-	I-Disease
Hodgkins	I-Disease
lymphoma	I-Disease
(	O
standardized	O
incidence	O
ratio	O
90	O
,	O
95	O
%	O
confidence	O
interval	O
18	O
to	O
264	O
)	O
.	O

The	O
cancer	B-Disease
incidence	O
among	O
the	O
siblings	O
or	O
the	O
parents	O
did	O
not	O
differ	O
from	O
the	O
average	O
cancer	B-Disease
incidence	O
in	O
the	O
Finnish	O
population	O
.	O

Genotype	O
and	O
phenotype	O
in	O
patients	O
with	O
dihydropyrimidine	B-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
.	O

In	O
order	O
to	O
understand	O
the	O
genetic	O
and	O
phenotypic	O
basis	O
for	O
DPD	B-Disease
deficiency	I-Disease
,	O
we	O
have	O
reviewed	O
17	O
families	O
presenting	O
22	O
patients	O
with	O
complete	O
deficiency	B-Disease
of	I-Disease
DPD	I-Disease
.	O

A	O
large	O
phenotypic	O
variability	O
has	O
been	O
observed	O
,	O
with	O
convulsive	B-Disease
disorders	I-Disease
,	O
motor	B-Disease
retardation	I-Disease
and	O
mental	B-Disease
retardation	I-Disease
being	O
the	O
most	O
abundant	O
manifestations	O
.	O

Fibroblast	O
growth	O
factor	O
homologous	O
factor	O
2	O
(	O
FHF2	O
)	O
:	O
gene	O
structure	O
,	O
expression	O
and	O
mapping	O
to	O
the	O
Borjeson	B-Disease
-	I-Disease
Forssman	I-Disease
-	I-Disease
Lehmann	I-Disease
syndrome	I-Disease
region	O
in	O
Xq26	O
delineated	O
by	O
a	O
duplication	O
breakpoint	O
in	O
a	O
BFLS	B-Disease
-	O
like	O
patient	O
.	O

We	O
have	O
identified	O
a	O
male	O
patient	O
with	O
BFLS	B-Disease
-	O
like	O
features	O
and	O
a	O
duplication	O
,	O
46	O
,	O
Y	O
,	O
dup	O
(	O
X	O
)	O
(	O
q26q28	O
)	O
,	O
inherited	O
from	O
his	O
phenotypically	O
normal	O
mother	O
.	O

Germline	O
E	O
-	O
cadherin	O
gene	O
(	O
CDH1	O
)	O
mutations	O
predispose	O
to	O
familial	B-Disease
gastric	I-Disease
cancer	I-Disease
and	O
colorectal	B-Disease
cancer	I-Disease
.	O

Familial	B-Disease
gastric	I-Disease
cancer	I-Disease
is	O
genetically	O
heterogeneous	O
and	O
it	O
is	O
not	O
clear	O
what	O
proportion	O
of	O
gastric	B-Disease
cancer	I-Disease
susceptibility	O
in	O
non	O
-	O
Maori	O
populations	O
is	O
due	O
to	O
germline	O
CDH1	O
mutations	O
.	O

Each	O
family	O
contained	O
(	O
i	O
)	O
two	O
cases	O
of	O
gastric	B-Disease
cancer	I-Disease
in	O
first	O
degree	O
relatives	O
with	O
one	O
affected	O
before	O
age	O
50	O
years	O
;	O
or	O
(	O
ii	O
)	O
three	O
or	O
more	O
cases	O
of	O
gastric	B-Disease
cancer	I-Disease
.	O

We	O
have	O
confirmed	O
that	O
germline	O
mutations	O
in	O
the	O
CDH1	O
gene	O
cause	O
familial	B-Disease
gastric	I-Disease
cancer	I-Disease
in	O
non	O
-	O
Maori	O
populations	O
.	O

Loss	O
of	O
E	O
-	O
cadherin	O
function	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
sporadic	O
colorectal	B-Disease
and	I-Disease
other	I-Disease
cancers	I-Disease
,	O
and	O
our	O
findings	O
provide	O
evidence	O
that	O
germline	O
CDH1	O
mutations	O
predispose	O
to	O
early	O
onset	O
colorectal	B-Disease
cancer	I-Disease
.	O

A	O
zinc	O
finger	O
truncation	O
of	O
murine	O
WT1	O
results	O
in	O
the	O
characteristic	O
urogenital	B-Disease
abnormalities	I-Disease
of	O
Denys	B-Disease
-	I-Disease
Drash	I-Disease
syndrome	I-Disease
.	O

The	O
analysis	O
of	O
diseases	O
linked	O
specifically	O
with	O
WT1	O
mutations	O
,	O
such	O
as	O
Denys	B-Disease
-	I-Disease
Drash	I-Disease
syndrome	I-Disease
(	O
DDS	B-Disease
)	O
,	O
can	O
provide	O
valuable	O
insight	O
concerning	O
the	O
role	O
of	O
WT1	O
in	O
development	O
and	O
disease	O
.	O

DDS	B-Disease
patients	O
are	O
constitutionally	O
heterozygous	O
for	O
exonic	O
point	O
mutations	O
in	O
WT1	O
,	O
which	O
include	O
mutations	O
predicted	O
to	O
truncate	O
the	O
protein	O
within	O
the	O
C	O
-	O
terminal	O
zinc	O
finger	O
(	O
ZF	O
)	O
region	O
.	O

Male	B-Disease
genital	I-Disease
defects	I-Disease
also	O
were	O
evident	O
and	O
there	O
was	O
a	O
single	O
case	O
of	O
Wilms	B-Disease
tumor	I-Disease
in	O
which	O
the	O
transcript	O
of	O
the	O
nontargeted	O
allele	O
showed	O
an	O
exon	O
9	O
skipping	O
event	O
,	O
implying	O
a	O
causal	O
link	O
between	O
Wt1	B-Disease
dysfunction	I-Disease
and	O
Wilms	B-Disease
tumorigenesis	I-Disease
in	O
mice	O
.	O

Mechanism	O
of	O
increased	O
iron	O
absorption	O
in	O
murine	O
model	O
of	O
hereditary	B-Disease
hemochromatosis	I-Disease
:	O
increased	O
duodenal	O
expression	O
of	O
the	O
iron	O
transporter	O
DMT1	O
.	O

We	O
recently	O
reported	O
that	O
HFE	O
,	O
the	O
protein	O
defective	O
in	O
HH	B-Disease
,	O
was	O
physically	O
associated	O
with	O
the	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
in	O
duodenal	O
crypt	O
cells	O
and	O
proposed	O
that	O
mutations	O
in	O
HFE	O
attenuate	O
the	O
uptake	O
of	O
transferrin	O
-	O
bound	O
iron	O
from	O
plasma	O
by	O
duodenal	O
crypt	O
cells	O
,	O
leading	O
to	O
up	O
-	O
regulation	O
of	O
transporters	O
for	O
dietary	O
iron	O
.	O

Neurophysiologic	O
follow	O
-	O
up	O
of	O
long	O
-	O
term	O
dietary	O
treatment	O
in	O
adult	O
-	O
onset	O
adrenoleukodystrophy	B-Disease
.	O

BACKGROUND	O
SEPs	O
and	O
MEPs	O
have	O
proved	O
useful	O
in	O
revealing	O
signs	O
of	O
progressively	O
severe	O
,	O
central	O
dying	B-Disease
-	I-Disease
back	I-Disease
axonopathy	I-Disease
in	O
early	O
stages	O
of	O
adult	O
-	O
onset	O
ALD	B-Disease
.	O

Three	O
of	O
these	O
patients	O
had	O
pure	O
spinal	B-Disease
SEP	I-Disease
abnormalities	I-Disease
and	O
in	O
the	O
remaining	O
two	O
patients	O
SEPs	O
showed	O
signs	O
of	O
involvement	O
of	O
both	O
the	O
spinal	O
and	O
cerebral	O
somatosensory	O
tracts	O
.	O

CONCLUSIONS	O
Lorenzos	O
oil	O
therapy	O
had	O
no	O
effect	O
on	O
patients	O
with	O
evidence	O
of	O
inflammatory	B-Disease
brain	I-Disease
lesions	I-Disease
.	O

The	O
authors	O
report	O
a	O
mutation	O
in	O
exon	O
5	O
of	O
GCH1	O
in	O
a	O
patient	O
with	O
adult	O
-	O
onset	O
oromandibular	B-Disease
dystonia	I-Disease
and	O
no	O
obvious	O
family	O
history	O
of	O
dystonia	B-Disease
.	O

Germline	O
mutations	O
of	O
the	O
APC	B-Disease
gene	O
in	O
Korean	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
patients	O
.	O

Nineteen	O
of	O
the	O
detected	O
mutations	O
were	O
presumed	O
to	O
be	O
novel	O
,	O
thus	O
emphasizing	O
the	O
heterogeneity	O
of	O
the	O
mutational	O
spectrum	O
in	O
Korean	O
FAP	B-Disease
patients	O
.	O

Our	O
results	O
confirm	O
that	O
the	O
mutation	O
detection	O
rate	O
with	O
PTT	O
was	O
superior	O
to	O
that	O
with	O
SSCP	O
,	O
and	O
suggest	O
that	O
PTT	O
would	O
be	O
a	O
more	O
practical	O
screening	O
method	O
to	O
detect	O
germline	O
mutations	O
of	O
the	O
APC	B-Disease
gene	O
in	O
FAP	B-Disease
patients	O
.	O

Deficiency	B-Disease
of	I-Disease
the	I-Disease
ninth	I-Disease
component	I-Disease
of	I-Disease
human	I-Disease
complement	I-Disease
(	O
C9	O
)	O
is	O
the	O
most	O
common	O
complement	B-Disease
deficiency	I-Disease
in	O
Japan	O
,	O
with	O
an	O
incidence	O
of	O
approximately	O
one	O
homozygote	O
in	O
1000	O
,	O
but	O
is	O
very	O
rare	O
in	O
other	O
countries	O
.	O

An	O
estimated	O
frequency	O
(	O
0	O
.	O
12	O
%	O
)	O
of	O
complete	O
C9	B-Disease
deficiency	I-Disease
due	O
to	O
homozygous	O
Arg95Stop	O
mutation	O
was	O
consistent	O
with	O
frequencies	O
determined	O
by	O
serological	O
studies	O

HFE	O
is	O
the	O
protein	O
product	O
of	O
the	O
gene	O
mutated	O
in	O
the	O
autosomal	B-Disease
recessive	I-Disease
disease	I-Disease
hereditary	B-Disease
hemochromatosis	I-Disease
(	O
Feder	O
,	O
J	O
.	O

Mutation	O
and	O
haplotype	O
studies	O
of	O
familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
reveal	O
new	O
ancestral	O
relationships	O
and	O
evidence	O
for	O
a	O
high	O
carrier	O
frequency	O
with	O
reduced	O
penetrance	O
in	O
the	O
Ashkenazi	O
Jewish	O
population	O
.	O

The	O
FMF	B-Disease
gene	O
(	O
MEFV	O
)	O
was	O
cloned	O
recently	O
,	O
and	O
four	O
missense	O
mutations	O
were	O
identified	O
.	O

Nevertheless	O
,	O
E148Q	O
helps	O
account	O
for	O
recessive	O
inheritance	O
in	O
an	O
Ashkenazi	O
family	O
previously	O
reported	O
as	O
an	O
unusual	O
case	O
of	O
dominantly	O
inherited	O
FMF	B-Disease
.	O

Autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
(	O
ALPS	B-Disease
)	O
is	O
a	O
disorder	B-Disease
of	I-Disease
lymphocyte	I-Disease
homeostasis	I-Disease
and	I-Disease
immunological	I-Disease
tolerance	I-Disease
.	O

Two	O
missense	O
Fas	O
variants	O
,	O
not	O
restricted	O
to	O
patients	O
with	O
ALPS	B-Disease
,	O
were	O
identified	O
.	O

Mutations	O
causing	O
disruption	O
of	O
the	O
intracellular	O
Fas	O
death	O
domain	O
also	O
showed	O
a	O
higher	O
penetrance	O
of	O
ALPS	B-Disease
phenotype	O
features	O
in	O
mutation	O
-	O
bearing	O
relatives	O
.	O

Thus	O
,	O
the	O
location	O
of	O
mutations	O
within	O
APT1	O
strongly	O
influences	O
the	O
development	O
and	O
the	O
severity	O
of	O
ALPS	B-Disease
.	O

Genetic	B-Disease
hemochromatosis	I-Disease
(	O
GH	B-Disease
)	O
is	O
believed	O
to	O
be	O
a	O
disease	O
restricted	O
to	O
those	O
of	O
European	O
ancestry	O
.	O

In	O
a	O
proportion	O
of	O
GH	B-Disease
patients	O
,	O
two	O
mutations	O
are	O
present	O
,	O
C282Y	O
and	O
H63D	O
.	O

We	O
have	O
retrospectively	O
analyzed	O
837	O
random	O
anonymized	O
dried	O
blood	O
spot	O
(	O
DBS	O
)	O
samples	O
from	O
neonatal	O
screening	O
programs	O
in	O
Scandinavia	O
for	O
mutations	O
in	O
HFE	O
,	O
the	O
candidate	O
gene	O
for	O
hemochromatosis	B-Disease
.	O

Alkaptonuria	B-Disease
(	O
aku	B-Disease
)	O
,	O
an	O
inborn	B-Disease
error	I-Disease
of	I-Disease
metabolism	I-Disease
caused	O
by	O
the	O
loss	O
of	O
homogentisate	O
1	O
,	O
2	O
-	O
dioxygenase	O
(	O
HGD	O
)	O
,	O
has	O
been	O
described	O
in	O
a	O
mouse	O
model	O
created	O
by	O
ethylnitrosourea	O
mutagenesis	O
but	O
the	O
mutation	O
in	O
these	O
mice	O
has	O
not	O
previously	O
been	O
identified	O
.	O

Enlarged	B-Disease
vestibular	I-Disease
aqueduct	I-Disease
(	O
EVA	B-Disease
)	O
,	O
known	O
as	O
the	O
most	O
common	O
form	O
of	O
inner	B-Disease
ear	I-Disease
abnormality	I-Disease
,	O
has	O
recently	O
been	O
of	O
particular	O
genetic	O
interest	O
because	O
this	O
anomaly	O
is	O
inherited	O
in	O
a	O
recessive	O
manner	O
.	O

In	O
the	O
present	O
study	O
,	O
seven	O
mutations	O
in	O
the	O
PDS	B-Disease
gene	O
(	O
PDS	O
)	O
,	O
the	O
gene	O
responsible	O
for	O
Pendred	B-Disease
syndrome	I-Disease
,	O
have	O
been	O
found	O
in	O
families	O
of	O
non	B-Disease
-	I-Disease
syndromic	I-Disease
sensorineural	I-Disease
hearing	I-Disease
loss	I-Disease
with	O
EVA	B-Disease
.	O

Mutational	O
analysis	O
and	O
genotype	O
-	O
phenotype	O
correlation	O
of	O
29	O
unrelated	O
Japanese	O
patients	O
with	O
X	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
.	O

The	O
classic	O
form	O
of	O
ALD	B-Disease
usually	O
has	O
onset	O
in	O
childhood	O
(	O
childhood	B-Disease
cerebral	I-Disease
ALD	I-Disease
)	O
,	O
with	O
rapid	O
neurologic	B-Disease
deterioration	I-Disease
leading	O
to	O
a	O
vegetative	O
state	O
.	O

Milder	O
phenotypes	O
such	O
as	O
adrenomyeloneuropathy	B-Disease
and	O
Addison	B-Disease
disease	I-Disease
only	O
also	O
have	O
been	O
recognized	O
.	O

METHODS	O
The	O
29	O
patients	O
comprised	O
13	O
patients	O
with	O
childhood	B-Disease
cerebral	I-Disease
ALD	I-Disease
,	O
11	O
patients	O
with	O
adult	O
-	O
onset	O
cerebral	B-Disease
ALD	I-Disease
,	O
and	O
5	O
patients	O
with	O
adrenomyeloneuropathy	B-Disease
.	O

RESULTS	O
Three	O
patients	O
with	O
adult	O
-	O
onset	O
cerebral	B-Disease
ALD	I-Disease
were	O
identified	O
as	O
having	O
large	O
genomic	O
rearrangements	O
.	O

CONCLUSIONS	O
There	O
are	O
no	O
obvious	O
correlations	O
between	O
the	O
phenotypes	O
of	O
patients	O
with	O
ALD	B-Disease
and	O
their	O
genotypes	O
,	O
suggesting	O
that	O
other	O
genetic	O
or	O
environmental	O
factors	O
modify	O
the	O
phenotypic	O
expressions	O
of	O
ALD	B-Disease
.	O
.	O

One	O
of	O
the	O
target	O
genes	O
for	O
beta	O
-	O
catenin	O
/	O
TCF	O
encodes	O
c	O
-	O
MYC	O
,	O
explaining	O
why	O
constitutive	O
activation	O
of	O
the	O
WNT	O
pathway	O
can	O
lead	O
to	O
cancer	B-Disease
,	O
particularly	O
in	O
the	O
colon	O
.	O

Recently	O
,	O
we	O
discovered	O
that	O
transgenic	O
mice	O
expressing	O
an	O
activated	O
beta	O
-	O
catenin	O
are	O
predisposed	O
to	O
developing	O
skin	B-Disease
tumours	I-Disease
resembling	O
pilomatricomas	B-Disease
.	O

Here	O
,	O
we	O
explore	O
the	O
cell	O
origin	O
and	O
aetiology	O
of	O
this	O
common	O
human	O
skin	B-Disease
tumour	I-Disease
.	O

At	O
least	O
75	O
%	O
of	O
these	O
tumours	B-Disease
possess	O
mutations	O
affecting	O
the	O
amino	O
-	O
terminal	O
segment	O
,	O
normally	O
involved	O
in	O
phosphorylation	O
-	O
dependent	O
,	O
ubiquitin	O
-	O
mediated	O
degradation	O
of	O
the	O
protein	O
.	O

The	O
Pendred	B-Disease
syndrome	I-Disease
gene	O
encodes	O
a	O
chloride	O
-	O
iodide	O
transport	O
protein	O
.	O

This	O
disorder	O
was	O
mapped	O
to	O
chromosome	O
7	O
and	O
the	O
gene	O
causing	O
Pendred	B-Disease
syndrome	I-Disease
(	O
PDS	B-Disease
)	O
was	O
subsequently	O
identified	O
by	O
positional	O
cloning	O
.	O

Our	O
results	O
demonstrate	O
that	O
pendrin	O
functions	O
as	O
a	O
transporter	O
of	O
chloride	O
and	O
iodide	O
,	O
but	O
not	O
sulfate	O
,	O
and	O
may	O
provide	O
insight	O
into	O
thyroid	O
physiology	O
and	O
the	O
pathophysiology	O
of	O
Pendred	B-Disease
syndrome	I-Disease
.	O
.	O

Hereditary	B-Disease
hemochromatosis	I-Disease
(	O
HH	B-Disease
)	O
is	O
a	O
common	O
autosomal	B-Disease
recessive	I-Disease
genetic	I-Disease
disorder	I-Disease
of	O
iron	O
metabolism	O
.	O

Two	O
missense	O
mutations	O
have	O
been	O
described	O
C282Y	O
,	O
accounting	O
for	O
80	O
%	O
to	O
90	O
%	O
of	O
HH	B-Disease
chromosomes	O
,	O
and	O
H63D	O
,	O
which	O
is	O
associated	O
with	O
a	O
milder	O
form	O
of	O
the	O
disease	O
representing	O
40	O
%	O
to	O
70	O
%	O
of	O
non	O
-	O
C282Y	O
HH	B-Disease
chromosomes	O
.	O

8	O
%	O
of	O
HH	B-Disease
chromosomes	O
that	O
were	O
neither	O
C282Y	O
nor	O
H63D	O
.	O

Germline	O
BRCA1	O
alterations	O
in	O
a	O
population	O
-	O
based	O
series	O
of	O
ovarian	B-Disease
cancer	I-Disease
cases	O
.	O

To	O
achieve	O
this	O
,	O
we	O
determined	O
the	O
prevalence	O
of	O
BRCA1	O
alterations	O
in	O
a	O
population	O
-	O
based	O
series	O
of	O
consecutive	O
ovarian	B-Disease
cancer	I-Disease
cases	O
.	O

One	O
hundred	O
and	O
seven	O
ovarian	B-Disease
cancer	I-Disease
cases	O
were	O
analyzed	O
for	O
BRCA1	O
alterations	O
using	O
the	O
RNase	O
mismatch	O
cleavage	O
assay	O
followed	O
by	O
direct	O
sequencing	O
.	O

Several	O
novel	O
as	O
well	O
as	O
previously	O
reported	O
uncharacterized	O
variants	O
were	O
also	O
identified	O
,	O
some	O
of	O
which	O
were	O
associated	O
with	O
a	O
family	O
history	O
of	O
cancer	B-Disease
.	O

The	O
rare	O
form	O
of	O
the	O
Q356R	O
polymorphism	O
was	O
significantly	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
associated	O
with	O
a	O
family	O
history	O
of	O
ovarian	B-Disease
cancer	I-Disease
,	O
suggesting	O
that	O
this	O
polymorphism	O
may	O
influence	O
ovarian	B-Disease
cancer	I-Disease
risk	O
.	O

Adrenoleukodystrophy	O
-	O
related	O
protein	O
can	O
compensate	O
functionally	O
for	O
adrenoleukodystrophy	B-Disease
protein	I-Disease
deficiency	I-Disease
(	O
X	B-Disease
-	I-Disease
ALD	I-Disease
)	O
:	O
implications	O
for	O
therapy	O
.	O

By	O
using	O
transient	O
and	O
stable	O
overexpression	O
of	O
human	O
cDNAs	O
encoding	O
ALDP	O
and	O
its	O
closest	O
relative	O
ALDRP	O
,	O
we	O
could	O
restore	O
the	O
impaired	O
peroxisomal	O
beta	O
-	O
oxidation	O
in	O
fibroblasts	O
of	O
X	B-Disease
-	I-Disease
ALD	I-Disease
patients	O
.	O

Germline	O
mutations	O
of	O
the	O
Brca1	O
tumor	B-Disease
suppressor	O
gene	O
predispose	O
women	O
to	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
.	O

Mutant	O
fibroblasts	O
contain	O
multiple	O
,	O
functional	O
centrosomes	O
,	O
which	O
lead	O
to	O
unequal	O
chromosome	O
segregation	O
,	O
abnormal	O
nuclear	O
division	O
,	O
and	O
aneuploidy	B-Disease
.	O

Heterozygous	O
mutations	O
in	O
the	O
CD95	O
(	O
APO	O
-	O
1	O
/	O
Fas	O
)	O
receptor	O
occur	O
in	O
most	O
individuals	O
with	O
autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
(	O
ALPS	B-Disease
)	O
and	O
dominantly	O
interfere	O
with	O
apoptosis	O
by	O
an	O
unknown	O
mechanism	O
.	O

Despite	O
heterozygosity	O
for	O
the	O
abnormal	O
allele	O
,	O
lymphocytes	O
from	O
ALPS	B-Disease
patients	O
showed	O
markedly	O
decreased	O
FADD	O
association	O
and	O
a	O
loss	O
of	O
caspase	O
recruitment	O
and	O
activation	O
after	O
CD95	O
crosslinking	O
.	O

Analysis	O
of	O
alkaptonuria	B-Disease
(	O
AKU	B-Disease
)	O
mutations	O
and	O
polymorphisms	O
reveals	O
that	O
the	O
CCC	O
sequence	O
motif	O
is	O
a	O
mutational	O
hot	O
spot	O
in	O
the	O
homogentisate	O
1	O
,	O
2	O
dioxygenase	O
gene	O
(	O
HGO	O
)	O
.	O

Herein	O
we	O
describe	O
haplotype	O
and	O
mutational	O
analyses	O
of	O
HGO	O
in	O
seven	O
new	O
AKU	B-Disease
pedigrees	O
.	O

Fabry	B-Disease
disease	I-Disease
:	O
identification	O
of	O
novel	O
alpha	O
-	O
galactosidase	O
A	O
mutations	O
and	O
molecular	O
carrier	O
detection	O
by	O
use	O
of	O
fluorescent	O
chemical	O
cleavage	O
of	O
mismatches	O
.	O

Clinically	O
,	O
affected	O
hemizygous	O
males	O
have	O
angiokeratoma	B-Disease
,	O
severe	B-Disease
acroparesthesia	I-Disease
,	O
renal	B-Disease
failure	I-Disease
,	O
and	O
vasculopathy	B-Disease
of	I-Disease
the	I-Disease
heart	I-Disease
and	I-Disease
brain	I-Disease
.	O

By	O
use	O
of	O
chemical	O
cleavage	O
of	O
mismatches	O
adapted	O
to	O
fluorescence	O
-	O
based	O
detection	O
systems	O
,	O
we	O
have	O
characterized	O
the	O
mutations	O
underlying	O
alpha	B-Disease
-	I-Disease
Gal	I-Disease
A	I-Disease
deficiency	I-Disease
in	O
16	O
individuals	O
from	O
six	O
unrelated	O
families	O
with	O
FD	B-Disease
.	O

A	O
diagnosis	O
of	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
(	O
MIM	O
312080	O
)	O
was	O
made	O
in	O
a	O
young	O
boy	O
.	O

Dominant	O
negative	O
effect	O
of	O
the	O
APC1309	O
mutation	O
:	O
a	O
possible	O
explanation	O
for	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
.	O

Patients	O
with	O
familial	B-Disease
APC	I-Disease
(	O
FAP	B-Disease
)	O
carry	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
APC	B-Disease
gene	O
and	O
develop	O
multiple	O
colorectal	B-Disease
adenomas	I-Disease
and	O
subsequent	O
carcinomas	B-Disease
early	O
in	O
life	O
.	O

Together	O
with	O
the	O
fact	O
that	O
both	O
germ	O
-	O
line	O
and	O
sporadic	O
APC	B-Disease
mutations	O
cluster	O
in	O
the	O
central	O
region	O
of	O
the	O
APC	B-Disease
gene	O
,	O
this	O
points	O
to	O
a	O
dominant	O
negative	O
effect	O
of	O
certain	O
APC	B-Disease
mutants	O
.	O

Here	O
,	O
we	O
provide	O
experimental	O
evidence	O
for	O
a	O
dominant	O
negative	O
effect	O
of	O
APC	B-Disease
gene	O
products	O
associated	O
with	O
severe	O
polyposis	B-Disease
.	O

In	O
contrast	O
,	O
mutant	O
APC	B-Disease
gene	O
products	O
that	O
are	O
associated	O
with	O
attenuated	B-Disease
polyposis	I-Disease
(	O
codon	O
386	O
or	O
1465	O
)	O
interfered	O
only	O
weakly	O
with	O
wild	O
-	O
type	O
APC	B-Disease
activity	O
.	O

Germ	O
-	O
line	O
mutations	O
in	O
the	O
BRCA1	O
tumor	O
-	O
suppressor	O
gene	O
are	O
associated	O
with	O
an	O
increased	O
susceptibility	O
to	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O

By	O
routine	O
screening	O
of	O
sera	O
,	O
a	O
subject	O
was	O
discovered	O
who	O
showed	O
a	O
sub	B-Disease
-	I-Disease
total	I-Disease
deficiency	I-Disease
of	I-Disease
C6	I-Disease
and	I-Disease
C7	I-Disease
.	O

Changes	O
at	O
P183	O
of	O
emerin	O
weaken	O
its	O
protein	O
-	O
protein	O
interactions	O
resulting	O
in	O
X	B-Disease
-	I-Disease
linked	I-Disease
Emery	I-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O

Mutations	O
spanning	O
the	O
emerin	O
gene	O
have	O
been	O
identified	O
in	O
patients	O
with	O
EDMD	B-Disease
.	O

In	O
comparison	O
with	O
the	O
usual	O
EDMD	B-Disease
phenotype	O
,	O
patients	O
with	O
P183	O
missense	O
mutations	O
have	O
a	O
later	O
age	O
at	O
onset	O
of	O
first	O
symptoms	O
,	O
elbow	B-Disease
contractures	I-Disease
,	O
ankle	B-Disease
contractures	I-Disease
,	O
upper	B-Disease
limb	I-Disease
weakness	I-Disease
and	O
lower	B-Disease
limb	I-Disease
weakness	I-Disease
,	O
but	O
there	O
is	O
no	O
difference	O
for	O
the	O
age	O
at	O
onset	O
of	O
cardiac	B-Disease
involvement	I-Disease
.	O

Microdeletions	O
at	O
chromosome	O
bands	O
1q32	O
-	O
q41	O
as	O
a	O
cause	O
of	O
Van	B-Disease
der	I-Disease
Woude	I-Disease
syndrome	I-Disease
.	O

Along	O
with	O
cleft	B-Disease
lip	I-Disease
/	I-Disease
palate	I-Disease
and	O
lip	B-Disease
pits	I-Disease
,	O
affected	O
relatives	O
exhibit	O
developmental	B-Disease
delays	I-Disease
,	O
suggesting	O
that	O
the	O
function	O
of	O
a	O
gene	O
nearby	O
may	O
also	O
be	O
disrupted	O
.	O

In	O
this	O
family	O
,	O
the	O
phenotype	O
in	O
three	O
generations	O
of	O
affected	O
individuals	O
was	O
confined	O
to	O
the	O
cardinal	O
signs	O
of	O
VWS	B-Disease
.	O

Splicing	O
defects	O
in	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
gene	O
,	O
ATM	O
:	O
underlying	O
mutations	O
and	O
consequences	O
.	O

No	O
ATM	O
protein	O
was	O
detected	O
by	O
western	O
blotting	O
in	O
any	O
AT	B-Disease
cell	O
line	O
in	O
which	O
splicing	O
mutations	O
were	O
identified	O
.	O

We	O
identified	O
the	O
alpha	O
-	O
cardiac	O
actin	O
gene	O
(	O
ACTC	O
)	O
as	O
a	O
novel	O
disease	O
gene	O
in	O
a	O
pedigree	O
suffering	O
from	O
familial	B-Disease
hypertrophic	I-Disease
cardiomyopathy	I-Disease
(	O
FHC	B-Disease
)	O
.	O

Mutation	O
analysis	O
of	O
ACTC	O
revealed	O
an	O
Ala295Ser	O
mutation	O
in	O
exon	O
5	O
close	O
to	O
2	O
missense	O
mutations	O
recently	O
described	O
to	O
cause	O
the	O
inherited	O
form	O
of	O
idiopathic	B-Disease
dilated	I-Disease
cardiomyopathy	I-Disease
(	O
IDC	B-Disease
)	O
.	O

Aspartylglucosaminuria	B-Disease
(	O
AGU	B-Disease
)	O
is	O
a	O
lysosomal	B-Disease
storage	I-Disease
disorder	I-Disease
caused	O
by	O
deficiency	B-Disease
of	I-Disease
aspartylglucosaminidase	I-Disease
(	O
AGA	O
)	O
.	O

We	O
were	O
able	O
to	O
examine	O
66	O
Finnish	O
AGU	B-Disease
patients	O
for	O
changes	O
in	O
the	O
oral	O
mucosa	O
and	O
44	O
of	O
these	O
for	O
changes	O
in	O
facial	O
skin	O
.	O

Skin	O
was	O
seborrhoeic	O
in	O
adolescent	O
and	O
adult	O
patients	O
,	O
with	O
erythema	B-Disease
of	I-Disease
the	I-Disease
facial	I-Disease
skin	I-Disease
already	O
common	O
in	O
childhood	O
.	O

Oedemic	B-Disease
buccal	I-Disease
mucosa	I-Disease
(	O
leucoedema	B-Disease
)	O
and	O
gingival	B-Disease
overgrowths	I-Disease
were	O
more	O
frequent	O
in	O
AGU	B-Disease
patients	O
than	O
in	O
controls	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Immunohistochemically	O
,	O
expression	O
of	O
AGA	O
in	O
AGU	B-Disease
patients	O
mucosal	B-Disease
lesions	I-Disease
did	O
not	O
differ	O
from	O
that	O
seen	O
in	O
corresponding	O
lesions	O
of	O
normal	O
subjects	O
.	O

Characterization	O
of	O
a	O
germline	O
mosaicism	O
in	O
families	O
with	O
Lowe	B-Disease
syndrome	I-Disease
,	O
and	O
identification	O
of	O
seven	O
novel	O
mutations	O
in	O
the	O
OCRL1	O
gene	O
.	O

We	O
have	O
examined	O
the	O
OCRL1	O
gene	O
in	O
eight	O
unrelated	O
patients	O
with	O
OCRL	B-Disease
and	O
have	O
found	O
seven	O
new	O
mutations	O
and	O
one	O
recurrent	O
in	O
-	O
frame	O
deletion	O
.	O

MEFV	O
-	O
Gene	O
analysis	O
in	O
armenian	O
patients	O
with	O
Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
:	O
diagnostic	O
value	O
and	O
unfavorable	O
renal	O
prognosis	O
of	O
the	O
M694V	O
homozygous	O
genotype	O
-	O
genetic	O
and	O
therapeutic	O
implications	O
.	O

To	O
date	O
,	O
its	O
diagnosis	O
,	O
which	O
can	O
be	O
made	O
only	O
retrospectively	O
,	O
is	O
one	O
of	O
exclusion	O
,	O
based	O
entirely	O
on	O
nonspecific	O
clinical	O
signs	O
that	O
result	O
from	O
serosal	B-Disease
inflammation	I-Disease
and	O
that	O
may	O
lead	O
to	O
unnecessary	O
surgery	O
.	O

To	O
evaluate	O
the	O
diagnostic	O
and	O
prognostic	O
value	O
of	O
MEFV	O
-	O
gene	O
analysis	O
,	O
we	O
investigated	O
90	O
Armenian	O
FMF	B-Disease
patients	O
from	O
77	O
unrelated	O
families	O
that	O
were	O
not	O
selected	O
through	O
genetic	O
-	O
linkage	O
analysis	O
.	O

The	O
M694V	O
homozygous	O
genotype	O
was	O
found	O
to	O
be	O
associated	O
with	O
a	O
higher	O
prevalence	O
of	O
renal	B-Disease
amyloidosis	I-Disease
and	O
arthritis	B-Disease
,	O
compared	O
with	O
other	O
genotypes	O
(	O
P	O
=	O
.	O
0002	O
and	O
P	O
=	O
.	O
006	O
,	O
respectively	O
)	O
.	O

Identification	O
of	O
the	O
FMR1	O
gene	O
and	O
the	O
repeat	O
-	O
amplification	O
mechanism	O
causing	O
fragile	B-Disease
X	I-Disease
syndrome	I-Disease
led	O
to	O
development	O
of	O
reliable	O
DNA	O
-	O
based	O
diagnostic	O
methods	O
,	O
including	O
Southern	O
blot	O
hybridization	O
and	O
PCR	O
.	O

Here	O
we	O
describe	O
a	O
new	O
diagnostic	O
test	O
to	O
identify	O
male	O
patients	O
with	O
fragile	B-Disease
X	I-Disease
syndrome	I-Disease
,	O
on	O
the	O
basis	O
of	O
lack	O
of	O
FMRP	O
in	O
their	O
hair	O
roots	O
.	O

Control	O
individuals	O
showed	O
clear	O
expression	O
of	O
FMRP	O
in	O
nearly	O
every	O
hair	O
root	O
,	O
whereas	O
male	O
fragile	B-Disease
X	I-Disease
patients	O
lacked	O
expression	O
of	O
FMRP	O
in	O
almost	O
all	O
their	O
hair	O
roots	O
.	O

The	O
advantages	O
of	O
this	O
test	O
are	O
(	O
1	O
)	O
plucking	O
of	O
hair	O
follicles	O
does	O
no	O
appreciable	O
harm	O
to	O
the	O
mentally	B-Disease
retarded	I-Disease
patient	O
,	O
(	O
2	O
)	O
hairs	O
can	O
be	O
sent	O
in	O
a	O
simple	O
envelope	O
to	O
a	O
diagnostic	O
center	O
,	O
and	O
(	O
3	O
)	O
the	O
result	O
of	O
the	O
test	O
is	O
available	O
within	O
5	O
h	O
of	O
plucking	O
.	O

In	O
Swedish	O
families	O
with	O
hereditary	B-Disease
prostate	I-Disease
cancer	I-Disease
,	O
linkage	O
to	O
the	O
HPC1	O
locus	O
on	O
chromosome	O
1q24	O
-	O
25	O
is	O
restricted	O
to	O
families	O
with	O
early	O
-	O
onset	O
prostate	B-Disease
cancer	I-Disease
.	O

We	O
previously	O
reported	O
evidence	O
of	O
linkage	O
to	O
the	O
1q24	O
-	O
25	O
region	O
(	O
HPC1	O
)	O
in	O
91	O
North	O
American	O
and	O
Swedish	O
families	O
each	O
with	O
multiple	O
cases	O
of	O
prostate	B-Disease
cancer	I-Disease
(	O
Smith	O
et	O
al	O
.	O
1996	O
)	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
of	O
linkage	O
to	O
HPC1	O
in	O
a	O
subset	O
of	O
families	O
with	O
prostate	B-Disease
cancer	I-Disease
,	O
particularly	O
those	O
with	O
an	O
early	O
age	O
at	O
diagnosis	O
.	O

A	O
family	O
of	O
domestic	O
cats	O
was	O
found	O
that	O
exhibited	O
clinical	O
and	O
biochemical	O
abnormalities	O
consistent	O
with	O
mucopolysaccharidosis	B-Disease
VII	I-Disease
,	O
an	O
autosomal	B-Disease
recessive	I-Disease
lysosomal	I-Disease
storage	I-Disease
disorder	I-Disease
caused	O
by	O
beta	B-Disease
-	I-Disease
glucuronidase	I-Disease
deficiency	I-Disease
.	O

A	O
common	O
molecular	O
basis	O
for	O
rearrangement	B-Disease
disorders	I-Disease
on	O
chromosome	O
22q11	O
.	O

Three	O
congenital	B-Disease
anomaly	I-Disease
disorders	I-Disease
,	O
cat	B-Disease
-	I-Disease
eye	I-Disease
syndrome	I-Disease
,	O
der	B-Disease
(	I-Disease
)	I-Disease
syndrome	I-Disease
and	O
velo	B-Disease
-	I-Disease
cardio	I-Disease
-	I-Disease
facial	I-Disease
syndrome	I-Disease
/	O
DiGeorge	B-Disease
syndrome	I-Disease
(	O
VCFS	B-Disease
/	O
DGS	B-Disease
)	O
are	O
associated	O
with	O
tetrasomy	O
,	O
trisomy	O
or	O
monosomy	O
,	O
respectively	O
,	O
for	O
part	O
of	O
chromosome	O
22q11	O
.	O

In	O
order	O
to	O
determine	O
whether	O
there	O
are	O
particular	O
regions	O
on	O
22q11	O
that	O
are	O
prone	O
to	O
rearrangements	O
,	O
the	O
deletion	O
end	O
-	O
points	O
in	O
a	O
large	O
number	O
of	O
VCFS	B-Disease
/	O
DGS	B-Disease
patients	O
were	O
defined	O
by	O
haplotype	O
analysis	O
.	O

To	O
investigate	O
this	O
hypothesis	O
,	O
we	O
developed	O
hamster	O
-	O
human	O
somatic	O
hybrid	O
cell	O
lines	O
from	O
VCFS	B-Disease
/	O
DGS	B-Disease
patients	O
with	O
all	O
three	O
classes	O
of	O
deletions	O
and	O
we	O
now	O
show	O
that	O
the	O
breakpoints	O
occur	O
within	O
similar	O
low	O
copy	O
repeats	O
,	O
termed	O
LCR22s	O
.	O

We	O
present	O
models	O
to	O
explain	O
how	O
the	O
LCR22s	O
can	O
mediate	O
different	O
homologous	O
recombination	O
events	O
,	O
thereby	O
generating	O
a	O
number	O
of	O
rearrangements	O
that	O
are	O
associated	O
with	O
congenital	B-Disease
anomaly	I-Disease
disorders	I-Disease
.	O

This	O
idea	O
is	O
based	O
partly	O
on	O
the	O
phenotype	O
of	O
homozygous	O
Krox20	O
(	O
Egr2	O
)	O
knockout	O
mice	O
,	O
which	O
display	O
hypomyelination	B-Disease
of	I-Disease
the	I-Disease
PNS	I-Disease
and	O
a	O
block	O
of	O
Schwann	O
cells	O
at	O
an	O
early	O
stage	O
of	O
differentiation	O
.	O

Autosomal	B-Disease
recessive	I-Disease
familial	I-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	I-Disease
with	O
continued	O
secretion	O
of	O
mutant	O
weakly	O
active	O
vasopressin	O
.	O

All	O
published	O
mutations	O
affect	O
the	O
signal	O
peptide	O
or	O
the	O
neurophysin	O
-	O
II	O
carrier	O
protein	O
and	O
are	O
presumed	O
to	O
interfere	O
with	O
processing	O
of	O
the	O
preprohormone	O
,	O
leading	O
to	O
neuronal	B-Disease
damage	I-Disease
.	O

The	O
youngest	O
child	O
(	O
2	O
years	O
old	O
)	O
was	O
only	O
mildly	O
affected	O
but	O
had	O
Leu	O
-	O
AVP	O
levels	O
similar	O
to	O
her	O
severely	O
affected	O
8	O
-	O
year	O
-	O
old	O
brother	O
,	O
suggesting	O
that	O
unknown	O
mechanisms	O
may	O
partially	O
compensate	O
for	O
a	O
deficiency	B-Disease
of	I-Disease
active	I-Disease
AVP	I-Disease
in	O
very	O
young	O
children	O
.	O
.	O

No	O
inherited	O
form	O
of	O
GPI	B-Disease
-	I-Disease
anchor	I-Disease
deficiency	I-Disease
has	O
been	O
described	O
.	O

PIGA	O
(	O
-	O
)	O
cells	O
had	O
no	O
growth	O
advantage	O
,	O
suggesting	O
that	O
other	O
factors	O
are	O
needed	O
for	O
their	O
clonal	O
dominance	O
in	O
patients	O
with	O
paroxysmal	B-Disease
nocturnal	I-Disease
hemoglobinuria	I-Disease
.	O
.	O

Targeted	O
mutagenesis	O
was	O
used	O
to	O
produce	O
two	O
mutations	O
in	O
the	O
murine	O
hemochromatosis	B-Disease
gene	O
(	O
Hfe	O
)	O
locus	O
.	O

Genotype	O
-	O
phenotype	O
analysis	O
in	O
X	B-Disease
-	I-Disease
linked	I-Disease
Emery	I-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
and	O
identification	O
of	O
a	O
missense	O
mutation	O
associated	O
with	O
a	O
milder	O
phenotype	O
.	O

Age	O
at	O
onset	O
was	O
later	O
for	O
first	O
symptoms	O
and	O
for	O
development	O
of	O
ankle	B-Disease
contractures	I-Disease
and	O
muscle	B-Disease
weakness	I-Disease
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
Emery	I-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
EDMD	B-Disease
)	O
is	O
a	O
relatively	O
rare	O
benign	B-Disease
neuromuscular	I-Disease
disorder	I-Disease
which	O
can	O
vary	O
remarkably	O
in	O
onset	O
,	O
course	O
and	O
severity	O
.	O

The	O
interfamilial	O
heterogeneity	O
in	O
distribution	O
and	O
in	O
severity	O
of	O
the	O
features	O
in	O
the	O
two	O
families	O
point	O
to	O
environmental	O
or	O
genetic	O
modification	O
as	O
the	O
cause	O
of	O
clinical	O
variability	O
in	O
Emery	B-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O
.	O

BACKGROUND	O
Families	O
with	O
a	O
high	O
incidence	O
of	O
hereditary	B-Disease
breast	I-Disease
cancer	I-Disease
,	O
and	O
subsequently	O
shown	O
to	O
have	O
terminating	O
mutations	O
in	O
BRCA1	O
or	O
BRCA2	O
,	O
appear	O
to	O
have	O
a	O
higher	O
incidence	O
of	O
prostate	B-Disease
cancer	I-Disease
among	O
male	O
relatives	O
.	O

METHODS	O
We	O
examined	O
genomic	O
DNA	O
from	O
83	O
(	O
for	O
BRCA1	O
185delAG	O
)	O
or	O
82	O
(	O
for	O
BRCA2	O
6174delT	O
)	O
Ashkenazi	O
Jewish	O
prostate	B-Disease
cancer	I-Disease
patients	O
,	O
most	O
of	O
whom	O
were	O
treated	O
at	O
a	O
relatively	O
young	O
age	O
,	O
for	O
the	O
most	O
common	O
germline	O
mutation	O
in	O
each	O
gene	O
seen	O
in	O
the	O
Ashkenazi	O
population	O
.	O

CONCLUSIONS	O
The	O
incidence	O
of	O
each	O
of	O
the	O
germline	O
mutations	O
in	O
these	O
prostate	B-Disease
cancer	I-Disease
patients	O
closely	O
matched	O
their	O
incidence	O
(	O
about	O
1	O
%	O
)	O
in	O
the	O
general	O
Ashkenazi	O
Jewish	O
population	O
.	O

Beta	O
-	O
catenin	O
accumulation	O
and	O
mutation	O
of	O
the	O
CTNNB1	O
gene	O
in	O
hepatoblastoma	B-Disease
.	O

Epidemiologic	O
studies	O
have	O
shown	O
an	O
increased	O
frequency	O
of	O
this	O
tumor	B-Disease
type	O
in	O
families	O
affected	O
by	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
.	O

In	O
an	O
ongoing	O
immunohistochemical	O
study	O
of	O
beta	O
-	O
catenin	O
expression	O
in	O
sporadic	O
cases	O
of	O
tumor	B-Disease
types	O
that	O
are	O
associated	O
with	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
,	O
we	O
observed	O
increased	O
beta	O
-	O
catenin	O
levels	O
in	O
the	O
cytoplasm	O
and	O
in	O
the	O
nuclei	O
of	O
three	O
investigated	O
hepatoblastomas	B-Disease
.	O

Our	O
data	O
indicate	O
for	O
the	O
first	O
time	O
that	O
beta	O
-	O
catenin	O
accumulation	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
hepatoblastoma	B-Disease
and	O
that	O
activating	O
mutations	O
of	O
the	O
beta	O
-	O
catenin	O
gene	O
may	O
substitute	O
biallelic	O
APC	O
inactivation	O
in	O
this	O
tumor	B-Disease
type	O
.	O

Hereditary	B-Disease
progressive	I-Disease
dystonia	I-Disease
with	O
marked	O
diurnal	O
fluctuation	O
(	O
HPD	B-Disease
;	O
dopa	B-Disease
-	I-Disease
responsive	I-Disease
dystonia	I-Disease
,	O
DRD	B-Disease
)	O
have	O
been	O
recently	O
found	O
to	O
be	O
caused	O
by	O
a	O
genetic	B-Disease
defect	I-Disease
in	O
the	O
GTP	O
cyclohydrolase	O
I	O
(	O
GCH1	O
)	O
gene	O
.	O

Sulfate	O
transport	O
is	O
not	O
impaired	O
in	O
pendred	B-Disease
syndrome	I-Disease
thyrocytes	O
.	O

The	O
gene	O
responsible	O
for	O
the	O
disease	O
(	O
PDS	B-Disease
)	O
has	O
been	O
cloned	O
,	O
but	O
its	O
function	O
is	O
as	O
yet	O
unknown	O
and	O
the	O
connection	O
between	O
thyroid	B-Disease
goiter	I-Disease
and	O
sensory	B-Disease
-	I-Disease
neural	I-Disease
deafness	I-Disease
remains	O
an	O
enigma	O
.	O

Small	O
deletions	O
in	O
the	O
type	O
II	O
collagen	O
triple	O
helix	O
produce	O
kniest	B-Disease
dysplasia	I-Disease
.	O

Mutations	O
in	O
the	O
gene	O
that	O
encodes	O
type	O
II	O
collagen	O
(	O
COL2A1	O
)	O
,	O
the	O
predominant	O
protein	O
of	O
cartilage	O
,	O
have	O
been	O
identified	O
in	O
a	O
number	O
of	O
individuals	O
with	O
Kniest	B-Disease
dysplasia	I-Disease
.	O

Sequencing	O
of	O
the	O
index	O
patients	O
genomic	O
DNA	O
identified	O
four	O
new	O
dominant	O
mutations	O
in	O
COL2A1	O
that	O
result	O
in	O
Kniest	B-Disease
dysplasia	I-Disease
a	O
21	O
-	O
bp	O
deletion	O
in	O
exon	O
16	O
,	O
an	O
18	O
-	O
bp	O
deletion	O
in	O
exon	O
19	O
,	O
and	O
4	O
-	O
bp	O
deletions	O
in	O
the	O
splice	O
donor	O
sites	O
of	O
introns	O
14	O
and	O
20	O
.	O

Classical	B-Disease
galactosemia	I-Disease
and	O
mutations	O
at	O
the	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyl	O
transferase	O
(	O
GALT	O
)	O
gene	O
.	O

The	O
considerable	O
genetic	O
heterogeneity	O
documented	O
to	O
date	O
undoubtedly	O
contributes	O
to	O
the	O
phenotypic	O
heterogeneity	O
that	O
is	O
observed	O
in	O
galactosemia	B-Disease
.	O

To	O
investigate	O
the	O
nature	O
of	O
somatic	O
von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	I-Disease
(	O
VHL	B-Disease
)	O
mutations	O
,	O
we	O
analyzed	O
173	O
primary	O
sporadic	O
human	O
renal	B-Disease
cell	I-Disease
carcinomas	I-Disease
for	O
mutations	O
of	O
the	O
VHL	B-Disease
tumor	I-Disease
suppressor	O
gene	O
,	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
analysis	O
(	O
SSCP	O
)	O
of	O
DNA	O
.	O

To	O
compare	O
somatic	O
and	O
germline	O
mutations	O
,	O
we	O
used	O
the	O
VHL	B-Disease
database	O
,	O
which	O
includes	O
507	O
mutations	O
.	O

We	O
then	O
analyzed	O
the	O
occurrence	O
of	O
RCC	B-Disease
in	O
VHL	B-Disease
families	O
,	O
based	O
on	O
the	O
nature	O
of	O
mutations	O
.	O

Thus	O
,	O
mutations	O
resulting	O
in	O
truncated	O
proteins	O
may	O
lead	O
to	O
a	O
higher	O
risk	O
of	O
RCC	B-Disease
in	O
VHL	B-Disease
patients	O

Chediak	B-Disease
-	I-Disease
Higashi	I-Disease
syndrome	I-Disease
(	O
CHS	B-Disease
)	O
is	O
an	O
inherited	B-Disease
disorder	I-Disease
caused	O
by	O
mutations	O
in	O
the	O
lysosomal	O
trafficking	O
regulator	O
gene	O
,	O
LYST	O
.	O

The	O
murine	O
equivalent	O
of	O
CHS	B-Disease
,	O
beige	O
mice	O
,	O
present	O
similar	O
characteristics	O
but	O
do	O
not	O
develop	O
the	O
lymphoproliferative	B-Disease
syndrome	I-Disease
.	O

It	O
is	O
therefore	O
proposed	O
that	O
the	O
defective	O
surface	O
expression	O
of	O
CTLA	O
-	O
4	O
by	O
CHS	B-Disease
T	O
cells	O
is	O
involved	O
in	O
the	O
generation	O
of	O
lymphoproliferative	B-Disease
disease	I-Disease
.	O

The	O
Clinical	O
European	O
Network	O
on	O
Brain	B-Disease
Dysmyelinating	I-Disease
Disease	I-Disease
.	O

Investigating	O
82	O
strictly	O
selected	O
sporadic	O
cases	O
of	O
PMD	B-Disease
,	O
we	O
found	O
PLP	O
mutations	O
in	O
77	O
%	O
;	O
complete	O
PLP	O
-	O
gene	O
duplications	O
were	O
the	O
most	O
frequent	O
abnormality	O
(	O
62	O
%	O
)	O
,	O
whereas	O
point	O
mutations	O
in	O
coding	O
or	O
splice	O
-	O
site	O
regions	O
of	O
the	O
gene	O
were	O
involved	O
less	O
frequently	O
(	O
38	O
%	O
)	O
.	O

Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
and	O
Angelman	B-Disease
syndrome	I-Disease
(	O
AS	B-Disease
)	O
are	O
distinct	O
neurobehavioral	B-Disease
disorders	I-Disease
that	O
most	O
often	O
arise	O
from	O
a	O
4	O
-	O
Mb	O
deletion	O
of	O
chromosome	O
15q11	O
-	O
q13	O
during	O
paternal	O
or	O
maternal	O
gametogenesis	O
,	O
respectively	O
.	O

Linkage	O
analysis	O
in	O
a	O
large	O
Brazilian	O
family	O
with	O
van	B-Disease
der	I-Disease
Woude	I-Disease
syndrome	I-Disease
suggests	O
the	O
existence	O
of	O
a	O
susceptibility	O
locus	O
for	O
cleft	B-Disease
palate	I-Disease
at	O
17p11	O
.	O
2	O
-	O
11	O
.	O
1	O
.	O

The	O
expression	O
of	O
VWS	B-Disease
,	O
which	O
has	O
incomplete	O
penetrance	O
,	O
is	O
highly	O
variable	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
have	O
conducted	O
linkage	O
analysis	O
in	O
a	O
large	O
Brazilian	O
kindred	O
with	O
VWS	B-Disease
,	O
considering	O
as	O
affected	O
the	O
individuals	O
with	O
CP	B-Disease
,	O
regardless	O
of	O
whether	O
it	O
is	O
associated	O
with	O
other	O
clinical	O
signs	O
of	O
VWS	B-Disease
.	O

If	O
this	O
hypothesis	O
is	O
confirmed	O
in	O
other	O
VWS	B-Disease
pedigrees	O
,	O
it	O
will	O
represent	O
one	O
of	O
the	O
first	O
examples	O
of	O
a	O
gene	O
,	O
mapped	O
through	O
linkage	O
analysis	O
,	O
which	O
modifies	O
the	O
expression	O
of	O
a	O
major	O
gene	O
.	O

Using	O
DNA	O
as	O
the	O
starting	O
material	O
,	O
we	O
screened	O
the	O
ATM	O
gene	O
in	O
92	O
A	B-Disease
-	I-Disease
T	I-Disease
patients	O
,	O
using	O
an	O
optimized	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
technique	O
that	O
detected	O
all	O
previously	O
known	O
mutations	O
in	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
segments	O
being	O
analyzed	O
.	O

We	O
report	O
a	O
novel	O
mutation	O
in	O
the	O
XK	O
gene	O
(	O
XK	O
)	O
in	O
a	O
Japanese	O
patient	O
with	O
McLeod	B-Disease
syndrome	I-Disease
.	O

We	O
conclude	O
this	O
single	O
-	O
base	O
deletion	O
causes	O
defective	O
Kx	O
protein	O
,	O
which	O
is	O
responsible	O
for	O
the	O
McLeod	B-Disease
phenotype	O
in	O
this	O
patient	O
.	O
.	O

Formation	O
of	O
irradiation	O
-	O
induced	O
foci	O
positive	O
for	O
BRCA1	O
,	O
hRad50	O
,	O
hMre11	O
,	O
or	O
p95	O
was	O
dramatically	O
reduced	O
in	O
HCC	O
/	O
1937	O
breast	B-Disease
cancer	I-Disease
cells	O
carrying	O
a	O
homozygous	O
mutation	O
in	O
BRCA1	O
but	O
was	O
restored	O
by	O
transfection	O
of	O
wild	O
-	O
type	O
BRCA1	O
.	O

OBJECTIVE	O
To	O
examine	O
the	O
relationship	O
of	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
genotypes	O
to	O
biochemical	O
phenotype	O
and	O
cognitive	O
development	O
in	O
maternal	B-Disease
phenylketonuria	I-Disease
(	O
PKU	B-Disease
)	O
.	O

Based	O
on	O
previous	O
knowledge	O
about	O
mutation	O
-	O
phenotype	O
associations	O
,	O
78	O
of	O
the	O
mutations	O
could	O
be	O
assigned	O
to	O
one	O
of	O
four	O
classes	O
of	O
severity	O
(	O
severe	O
PKU	B-Disease
,	O
moderate	O
PKU	B-Disease
,	O
mild	O
PKU	B-Disease
,	O
and	O
mild	B-Disease
hyperphenylalaninemia	I-Disease
[	O
MHP	B-Disease
]	O
)	O
.	O

Of	O
the	O
patients	O
with	O
PKU	B-Disease
,	O
92	O
%	O
had	O
been	O
treated	O
during	O
childhood	O
.	O

CONCLUSIONS	O
The	O
reproductive	O
outcome	O
in	O
maternal	B-Disease
phenylketonuria	I-Disease
is	O
dependent	O
on	O
prenatal	O
metabolic	O
control	O
and	O
postnatal	O
environmental	O
circumstances	O
.	O

The	O
significant	O
relationship	O
among	O
genotype	O
,	O
biochemical	O
phenotype	O
,	O
and	O
cognitive	O
performance	O
observed	O
in	O
the	O
present	O
study	O
is	O
of	O
importance	O
for	O
the	O
development	O
of	O
an	O
optimal	O
strategy	O
for	O
future	O
treatment	O
of	O
females	O
with	O
PKU	B-Disease
who	O
plan	O
pregnancy	O
.	O
.	O

We	O
describe	O
seven	O
Dutch	O
patients	O
from	O
six	O
families	O
with	O
a	O
slowly	O
progressive	O
,	O
mainly	O
spinal	B-Disease
cord	I-Disease
syndrome	I-Disease
that	O
remained	O
for	O
many	O
years	O
the	O
sole	O
expression	O
of	O
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
(	O
CTX	B-Disease
)	O
.	O

We	O
conclude	O
that	O
spinal	B-Disease
xanthomatosis	I-Disease
is	O
a	O
clinical	O
and	O
radiological	O
separate	O
entity	O
of	O
CTX	B-Disease
that	O
should	O
be	O
included	O
in	O
the	O
differential	O
diagnosis	O
of	O
chronic	B-Disease
myelopathy	I-Disease
.	O
.	O

Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
and	O
Angelman	B-Disease
syndrome	I-Disease
(	O
AS	B-Disease
)	O
result	O
from	O
the	O
loss	O
of	O
function	O
of	O
imprinted	O
genes	O
in	O
human	O
chromosome	O
15q11	O
-	O
q13	O
.	O

Epigenotype	O
(	O
allelic	O
expression	O
and	O
DNA	O
methylation	O
)	O
and	O
fluorescence	O
in	O
situ	O
hybridization	O
analyses	O
indicate	O
that	O
the	O
transgene	O
-	O
induced	O
mutation	O
has	O
generated	O
a	O
complete	O
deletion	O
of	O
the	O
PWS	B-Disease
/	O
AS	B-Disease
-	O
homologous	O
region	O
but	O
has	O
not	O
deleted	O
flanking	O
loci	O
.	O

This	O
heritable	O
-	O
deletion	O
mouse	O
model	O
will	O
be	O
particularly	O
useful	O
for	O
the	O
identification	O
of	O
the	O
etiological	O
genes	O
and	O
mechanisms	O
,	O
phenotypic	O
basis	O
,	O
and	O
investigation	O
of	O
therapeutic	O
approaches	O
for	O
PWS	B-Disease
.	O
.	O

van	B-Disease
der	I-Disease
Woude	I-Disease
syndrome	I-Disease
(	O
vWS	B-Disease
,	O
MIM	O
119300	O
)	O
is	O
a	O
rare	O
autosomal	B-Disease
dominant	I-Disease
clefting	I-Disease
condition	I-Disease
with	O
cardinal	O
features	O
of	O
mucous	B-Disease
cysts	I-Disease
(	O
lower	B-Disease
-	I-Disease
lip	I-Disease
pits	I-Disease
)	O
and	O
clefts	B-Disease
to	I-Disease
the	I-Disease
lip	I-Disease
and	I-Disease
/	I-Disease
or	I-Disease
palate	I-Disease
.	O

We	O
have	O
investigated	O
5	O
novel	O
vWS	B-Disease
families	O
through	O
probands	O
attended	O
for	O
cleft	B-Disease
lip	I-Disease
and	I-Disease
/	I-Disease
or	I-Disease
palate	I-Disease
repair	O
at	O
the	O
Department	O
of	O
Maxillofacial	O
Surgery	O
of	O
Hopital	O
Trousseau	O
,	O
Paris	O
,	O
in	O
order	O
to	O
tentatively	O
refine	O
the	O
genetic	O
map	O
of	O
the	O
vWS	B-Disease
region	O
in	O
1q32	O
-	O
q41	O
and	O
possibly	O
identify	O
unlinked	O
pedigrees	O
.	O

Null	O
mutation	O
of	O
the	O
murine	O
ATP7B	O
(	O
Wilson	B-Disease
disease	I-Disease
)	O
gene	O
results	O
in	O
intracellular	B-Disease
copper	I-Disease
accumulation	I-Disease
and	O
late	B-Disease
-	I-Disease
onset	I-Disease
hepatic	I-Disease
nodular	I-Disease
transformation	I-Disease
.	O

Using	O
homologous	O
recombination	O
to	O
disrupt	O
the	O
normal	O
translation	O
of	O
ATP7B	O
,	O
we	O
have	O
generated	O
a	O
strain	O
of	O
mice	O
that	O
are	O
homozygous	O
mutants	O
(	O
null	O
)	O
for	O
the	O
Wilson	B-Disease
disease	I-Disease
gene	O
.	O

Morphological	B-Disease
abnormalities	I-Disease
resembling	O
cirrhosis	B-Disease
developed	O
in	O
the	O
majority	O
of	O
the	O
livers	O
from	O
homozygous	O
mutants	O
older	O
than	O
7	O
months	O
of	O
age	O
.	O

In	O
summary	O
,	O
inactivation	O
of	O
the	O
murine	O
ATP7B	O
gene	O
produces	O
a	O
form	O
of	O
cirrhotic	B-Disease
liver	I-Disease
disease	I-Disease
that	O
resembles	O
Wilson	B-Disease
disease	I-Disease
in	O
humans	O
and	O
the	O
toxic	O
milk	O
phenotype	O
in	O
the	O
mouse	O
.	O
.	O

Segregation	O
distortion	O
has	O
been	O
reported	O
to	O
occur	O
in	O
a	O
number	O
of	O
the	O
trinucleotide	B-Disease
repeat	I-Disease
disorders	I-Disease
.	O

We	O
performed	O
a	O
sperm	O
typing	O
study	O
of	O
five	O
MJD	B-Disease
patients	O
of	O
French	O
descent	O
and	O
analysis	O
of	O
the	O
pooled	O
data	O
shows	O
a	O
ratio	O
of	O
mutant	O
to	O
normal	O
alleles	O
of	O
379	O
436	O
(	O
46	O
.	O
5	O
53	O
.	O
5	O
%	O
)	O
,	O
which	O
does	O
not	O
support	O
meiotic	O
segregation	O
distortion	O
.	O

Missense	O
mutation	O
in	O
the	O
alternative	O
splice	O
region	O
of	O
the	O
PAX6	O
gene	O
in	O
eye	B-Disease
anomalies	I-Disease
.	O

We	O
ascertained	O
a	O
novel	O
missense	O
mutation	O
in	O
four	O
pedigrees	O
with	O
Peters	B-Disease
anomaly	I-Disease
,	O
congenital	B-Disease
cataract	I-Disease
,	O
Axenfeldt	B-Disease
anomaly	I-Disease
,	O
and	O
/	O
or	O
foveal	B-Disease
hypoplasia	I-Disease
,	O
which	O
,	O
to	O
our	O
knowledge	O
,	O
is	O
the	O
first	O
mutation	O
identified	O
in	O
the	O
splice	O
-	O
variant	O
region	O
.	O

For	O
genetic	O
counseling	O
and	O
predictive	O
testing	O
in	O
families	O
with	O
inherited	B-Disease
breast	I-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
,	O
penetrances	O
and	O
expressions	O
of	O
the	O
underlying	O
mutations	O
should	O
be	O
known	O
.	O

Their	O
relatives	O
were	O
described	O
with	O
respect	O
to	O
absence	O
/	O
presence	O
of	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O

More	O
ovarian	B-Disease
cancers	I-Disease
than	O
breast	B-Disease
cancers	I-Disease
were	O
recorded	O
.	O

The	O
dermatofibrosarcoma	B-Disease
protuberans	I-Disease
-	O
associated	O
collagen	O
type	O
Ialpha1	O
/	O
platelet	O
-	O
derived	O
growth	O
factor	O
(	O
PDGF	O
)	O
B	O
-	O
chain	O
fusion	O
gene	O
generates	O
a	O
transforming	O
protein	O
that	O
is	O
processed	O
to	O
functional	O
PDGF	O
-	O
BB	O
.	O

Finally	O
,	O
COLIA1	O
/	O
PDGFB	O
-	O
expressing	O
cells	O
generated	O
tumors	B-Disease
after	O
s	O
.	O

We	O
conclude	O
that	O
the	O
COLIA1	O
/	O
PDGFB	O
fusion	O
associated	O
with	O
DFSP	B-Disease
contributes	O
to	O
tumor	B-Disease
development	O
through	O
ectopic	O
production	O
of	O
PDGF	O
-	O
BB	O
and	O
the	O
formation	O
of	O
an	O
autocrine	O
loop	O
.	O

Identification	O
of	O
a	O
common	O
PEX1	O
mutation	O
in	O
Zellweger	B-Disease
syndrome	I-Disease
.	O

However	O
,	O
previous	O
studies	O
have	O
focused	O
on	O
mildly	O
affected	O
patients	O
and	O
there	O
is	O
still	O
no	O
report	O
of	O
two	O
mutant	O
PEX1	O
alleles	O
in	O
any	O
Zellweger	B-Disease
syndrome	I-Disease
patient	O
.	O

To	O
address	O
the	O
molecular	O
basis	O
of	O
disease	O
in	O
Zellweger	B-Disease
syndrome	I-Disease
patients	O
from	O
CG1	O
,	O
we	O
examined	O
all	O
24	O
PEX1	O
exons	O
in	O
four	O
patients	O
,	O
including	O
both	O
patients	O
that	O
have	O
mutations	O
in	O
PMP70	O
.	O

As	O
this	O
mutation	O
leads	O
to	O
a	O
loss	O
of	O
protein	O
function	O
its	O
frequency	O
makes	O
it	O
the	O
most	O
common	O
cause	O
of	O
Zellweger	B-Disease
syndrome	I-Disease
,	O
helping	O
to	O
explain	O
the	O
high	O
percentage	O
of	O
patients	O
that	O
belong	O
to	O
CG1	O
.	O

Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
(	O
WAS	B-Disease
)	O
is	O
an	O
X	B-Disease
-	I-Disease
linked	I-Disease
recessive	I-Disease
immunodeficiency	I-Disease
characterized	O
by	O
thrombocytopenia	B-Disease
,	O
eczema	B-Disease
,	O
and	O
recurrent	O
infections	O
,	O
and	O
caused	O
by	O
mutations	O
in	O
the	O
WAS	B-Disease
protein	O
(	O
WASP	O
)	O
gene	O
.	O

Reduced	O
levels	O
of	O
a	O
normal	O
-	O
size	O
WASP	O
with	O
a	O
missense	O
mutation	O
were	O
seen	O
in	O
two	O
individuals	O
with	O
XLT	B-Disease
.	O

On	O
the	O
basis	O
of	O
the	O
observation	O
that	O
aminoglycoside	O
treatment	O
can	O
suppress	O
stop	O
codons	O
in	O
cultured	O
cells	O
,	O
we	O
tested	O
the	O
effect	O
of	O
gentamicin	O
on	O
cultured	O
muscle	O
cells	O
from	O
the	O
mdx	O
mouse	O
-	O
an	O
animal	O
model	O
for	O
DMD	B-Disease
that	O
possesses	O
a	O
premature	O
stop	O
codon	O
in	O
the	O
dystrophin	O
gene	O
.	O

Furthermore	O
,	O
these	O
results	O
raise	O
the	O
possibility	O
of	O
a	O
novel	O
treatment	O
regimen	O
for	O
muscular	B-Disease
dystrophy	I-Disease
and	O
other	O
diseases	O
caused	O
by	O
premature	O
stop	O
codon	O
mutations	O
.	O

Loss	O
of	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
gene	O
product	O
causes	O
oxidative	O
damage	O
in	O
target	O
organs	O
.	O

We	O
therefore	O
hypothesized	O
that	O
A	B-Disease
-	I-Disease
T	I-Disease
is	O
due	O
to	O
oxidative	O
damage	O
resulting	O
from	O
loss	O
of	O
function	O
of	O
the	O
A	B-Disease
-	I-Disease
T	I-Disease
gene	O
product	O
.	O

These	O
observations	O
provide	O
a	O
mechanistic	O
basis	O
for	O
the	O
A	B-Disease
-	I-Disease
T	I-Disease
phenotype	O
and	O
lay	O
a	O
rational	O
foundation	O
for	O
therapeutic	O
intervention	O
.	O
.	O

We	O
have	O
observed	O
over	O
25	O
different	O
mutations	O
in	O
the	O
diastrophic	B-Disease
dysplasia	I-Disease
sulphate	O
transporter	O
gene	O
(	O
DTDST	O
)	O
in	O
association	O
with	O
the	O
recessive	B-Disease
disorders	I-Disease
achondrogenesis	B-Disease
1B	I-Disease
,	O
atelosteogenesis	B-Disease
2	I-Disease
,	O
and	O
diastrophic	B-Disease
dysplasia	I-Disease
.	O

He	O
was	O
treated	O
for	O
club	B-Disease
foot	I-Disease
and	O
hip	B-Disease
dysplasia	I-Disease
at	O
birth	O
.	O

Cleft	B-Disease
palate	I-Disease
,	O
swelling	B-Disease
of	I-Disease
the	I-Disease
ear	I-Disease
pinna	I-Disease
,	O
and	O
hitch	B-Disease
hiker	I-Disease
thumb	I-Disease
were	O
absent	O
.	O

Counselling	O
was	O
given	O
for	O
a	O
recessive	B-Disease
disorder	I-Disease
,	O
thereby	O
considerably	O
reducing	O
the	O
probability	O
of	O
affected	O
offspring	O
.	O

A	O
few	O
other	O
patients	O
and	O
families	O
with	O
features	O
similar	O
to	O
our	O
proband	O
have	O
been	O
described	O
previously	O
and	O
considered	O
to	O
have	O
autosomal	O
recessive	O
MED	B-Disease
(	O
EDM4	B-Disease
,	O
McKusick	O
226900	O
)	O
.	O

Atypical	O
or	O
variant	O
forms	O
of	O
well	O
-	O
known	O
chondrodysplasias	B-Disease
may	O
pose	O
diagnostic	O
problems	O
.	O

The	O
type	O
of	O
somatic	O
mutation	O
at	O
APC	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
is	O
determined	O
by	O
the	O
site	O
of	O
the	O
germline	O
mutation	O
:	O
a	O
new	O
facet	O
to	O
Knudson	O
'	O
s	O
'	O
two	O
-	O
hit	O
'	O
hypothesis	O
.	O

Truncating	O
germline	O
and	O
somatic	O
mutations	O
(	O
or	O
,	O
infrequently	O
,	O
allelic	O
loss	O
)	O
occur	O
in	O
tumors	B-Disease
in	O
FAP	B-Disease
(	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
)	O
.	O

Clues	O
from	O
attenuated	B-Disease
polyposis	I-Disease
,	O
missense	O
germline	O
variants	O
with	O
mild	O
disease	O
and	O
the	O
somatic	O
mutation	O
cluster	O
region	O
(	O
codons	O
1	O
,	O
250	O
-	O
1	O
,	O
450	O
)	O
indicate	O
,	O
however	O
,	O
that	O
APC	B-Disease
mutations	O
might	O
not	O
result	O
in	O
simple	O
loss	O
of	O
protein	O
function	O
.	O

Our	O
results	O
indicate	O
that	O
different	O
APC	B-Disease
mutations	O
provide	O
cells	O
with	O
different	O
selective	O
advantages	O
,	O
with	O
mutations	O
close	O
to	O
codon	O
1	O
,	O
300	O
providing	O
the	O
greatest	O
advantage	O
.	O

APC	O
is	O
not	O
,	O
therefore	O
,	O
a	O
classical	O
tumor	B-Disease
suppressor	O
.	O

Mxi1	O
mutations	O
in	O
human	O
neurofibrosarcomas	B-Disease
.	O

Little	O
effort	O
has	O
yet	O
been	O
made	O
to	O
find	O
alterations	O
involving	O
this	O
gene	O
in	O
human	O
solid	B-Disease
tumors	I-Disease
.	O

We	O
also	O
examined	O
29	O
human	O
tumor	B-Disease
cell	O
lines	O
consisting	O
of	O
12	O
esophageal	B-Disease
cancers	I-Disease
,	O
7	O
glioma	B-Disease
/	O
glioblastomas	B-Disease
and	O
10	O
others	O
for	O
Mxi1	O
mutations	O
in	O
exons	O
1	O
,	O
2	O
,	O
4	O
(	O
HLH	O
domain	O
)	O
,	O
5	O
and	O
6	O
.	O

Our	O
data	O
demonstrate	O
that	O
mutations	O
occur	O
in	O
the	O
Mxi1	O
gene	O
in	O
neurofibrosarcoma	B-Disease
.	O

A	O
population	O
-	O
based	O
study	O
of	O
the	O
clinical	O
expression	O
of	O
the	O
hemochromatosis	B-Disease
gene	O
.	O

Four	O
of	O
the	O
homozygous	O
subjects	O
had	O
previously	O
been	O
given	O
a	O
diagnosis	O
of	O
hemochromatosis	B-Disease
,	O
and	O
12	O
had	O
not	O
.	O

Eight	O
of	O
the	O
16	O
homozygous	O
subjects	O
had	O
clinical	O
findings	O
that	O
were	O
consistent	O
with	O
the	O
presence	O
of	O
hereditary	B-Disease
hemochromatosis	I-Disease
,	O
such	O
as	O
hepatomegaly	B-Disease
,	O
skin	B-Disease
pigmentation	I-Disease
,	O
and	O
arthritis	B-Disease
.	O

The	O
clinical	O
use	O
of	O
molecular	O
analyses	O
in	O
recessive	B-Disease
disorders	I-Disease
relies	O
on	O
the	O
exact	O
characterization	O
of	O
both	O
mutant	O
alleles	O
in	O
the	O
affected	O
patient	O
.	O

Early	O
onset	O
of	O
X	B-Disease
-	I-Disease
linked	I-Disease
Emery	I-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
in	O
a	O
boy	O
with	O
emerin	O
gene	O
deletion	O
.	O

These	O
results	O
confirmed	O
the	O
diagnosis	O
of	O
X	B-Disease
-	I-Disease
linked	I-Disease
Emery	I-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
EDMD	B-Disease
)	O
,	O
and	O
reinforce	O
the	O
necessity	O
of	O
molecular	O
genetic	O
diagnosis	O
of	O
the	O
membrane	O
protein	O
emerin	O
in	O
younger	O
patients	O
with	O
possible	O
EDMD	B-Disease
before	O
appearance	O
of	O
the	O
typical	O
symptoms	O
,	O
to	O
avoid	O
sudden	B-Disease
cardiac	I-Disease
death	I-Disease
.	O
.	O

The	O
dark	O
-	O
adapted	O
electroretinogram	O
(	O
ERG	O
)	O
of	O
patients	O
with	O
Duchenne	B-Disease
and	I-Disease
Becker	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
/	O
BMD	B-Disease
)	O
shows	O
a	O
marked	O
reduction	O
in	O
b	O
-	O
wave	O
amplitude	O
.	O

We	O
have	O
undertaken	O
a	O
systematic	O
evaluation	O
of	O
DMD	B-Disease
/	O
BMD	B-Disease
patients	O
through	O
clinical	O
examination	O
and	O
review	O
of	O
the	O
literature	O
in	O
order	O
to	O
determine	O
whether	O
the	O
position	O
-	O
specific	O
effects	O
of	O
mutations	O
noted	O
in	O
the	O
mouse	O
are	O
present	O
in	O
man	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
most	O
important	O
determinant	O
in	O
the	O
ERG	O
b	O
-	O
wave	O
phenotype	O
is	O
the	O
mutation	O
position	O
,	O
rather	O
than	O
muscle	B-Disease
disease	I-Disease
severity	O
.	O

The	O
mutation	O
causing	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
has	O
been	O
identified	O
as	O
a	O
CTG	O
expansion	O
in	O
the	O
3	O
-	O
untranslated	O
region	O
(	O
3	O
-	O
UTR	O
)	O
of	O
the	O
DM	B-Disease
protein	O
kinase	O
gene	O
(	O
DMPK	O
)	O
,	O
but	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
pathogenesis	O
remain	O
unknown	O
.	O

Therefore	O
,	O
to	O
study	O
the	O
effects	O
of	O
the	O
DM	B-Disease
mutation	O
in	O
a	O
controlled	O
environment	O
,	O
we	O
have	O
established	O
a	O
cell	O
culture	O
model	O
system	O
using	O
C2C12	O
mouse	O
myoblasts	O
.	O

These	O
results	O
provide	O
evidence	O
that	O
the	O
DM	B-Disease
mutation	O
acts	O
in	O
cis	O
to	O
reduce	O
protein	O
production	O
(	O
consistent	O
with	O
DMPK	B-Disease
haploinsufficiency	I-Disease
)	O
and	O
in	O
trans	O
as	O
a	O
riboregulator	O
to	O
inhibit	O
myogenesis	O
.	O
.	O

Coats	B-Disease
disease	I-Disease
is	O
characterized	O
by	O
abnormal	B-Disease
retinal	I-Disease
vascular	I-Disease
development	I-Disease
(	O
so	O
-	O
called	O
retinal	B-Disease
telangiectasis	I-Disease
)	O
which	O
results	O
in	O
massive	O
intraretinal	B-Disease
and	I-Disease
subretinal	I-Disease
lipid	I-Disease
accumulation	I-Disease
(	O
exudative	B-Disease
retinal	I-Disease
detachment	I-Disease
)	O
.	O

A	O
female	O
with	O
a	O
unilateral	O
variant	O
of	O
Coats	B-Disease
disease	I-Disease
gave	O
birth	O
to	O
a	O
son	O
affected	O
by	O
Norrie	B-Disease
disease	I-Disease
.	O

We	O
suggest	O
that	O
Coats	B-Disease
telangiectasis	I-Disease
is	O
secondary	O
to	O
somatic	O
mutation	O
in	O
the	O
NDP	O
gene	O
which	O
results	O
in	O
a	O
deficiency	B-Disease
of	I-Disease
norrin	I-Disease
(	O
the	O
protein	O
product	O
of	O
the	O
NDP	O
gene	O
)	O
within	O
the	O
developing	O
retina	O
.	O

Li	B-Disease
-	I-Disease
Fraumeni	I-Disease
syndrome	I-Disease
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disorder	I-Disease
that	O
is	O
characterized	O
by	O
various	O
types	O
of	O
cancer	B-Disease
in	O
childhood	O
and	O
adult	O
cases	O
.	O

On	O
the	O
other	O
hand	O
,	O
hereditary	O
mutations	O
of	O
TP57KIP2	O
,	O
P15INK4B	O
,	O
and	O
P16INK4A	O
,	O
which	O
affect	O
the	O
cell	O
cycle	O
similar	O
to	O
TP53	O
,	O
were	O
observed	O
in	O
some	O
types	O
of	O
cancer	B-Disease
.	O

The	O
propositus	O
had	O
a	O
seminoma	B-Disease
,	O
his	O
daughter	O
a	O
medulloblastoma	B-Disease
,	O
and	O
one	O
of	O
his	O
healthy	O
cousins	O
,	O
a	O
TP53	O
codon	O
292	O
missense	O
point	O
mutation	O
(	O
AAA	O
-	O
-	O
>	O
ATA	O
;	O
Lys	O
-	O
-	O
>	O
Ile	O
)	O
in	O
the	O
peripheral	O
blood	O
cells	O
.	O

In	O
the	O
analyses	O
of	O
tumor	B-Disease
tissues	O
from	O
the	O
propositus	O
and	O
his	O
daughter	O
,	O
a	O
P16INK4A	O
codon	O
94	O
missense	O
point	O
mutation	O
(	O
GCG	O
-	O
-	O
>	O
GAG	O
;	O
Ala	O
-	O
-	O
>	O
Glu	O
)	O
was	O
observed	O
with	O
the	O
hereditary	O
TP53	O
mutation	O
.	O

Existence	O
of	O
the	O
P16INK4A	O
mutation	O
and	O
the	O
hereditary	O
TP53	O
mutation	O
with	O
or	O
without	O
loss	O
of	O
heterozygosity	O
in	O
the	O
TP53	O
gene	O
(	O
seminoma	B-Disease
/	O
medulloblastoma	B-Disease
)	O
may	O
be	O
evidence	O
for	O
a	O
common	O
mechanism	O
involved	O
in	O
tumorogenesis	B-Disease
.	O

A	O
novel	O
mutation	O
in	O
the	O
sodium	O
/	O
iodide	O
symporter	O
gene	O
in	O
the	O
largest	O
family	O
with	O
iodide	B-Disease
transport	I-Disease
defect	I-Disease
.	O

Since	O
the	O
original	O
report	O
,	O
we	O
have	O
diagnosed	O
congenital	B-Disease
hypothyroidism	I-Disease
by	O
newborn	O
TSH	O
screening	O
in	O
9	O
additional	O
children	O
from	O
the	O
family	O
.	O

It	O
is	O
now	O
possible	O
to	O
use	O
gene	O
diagnostics	O
of	O
this	O
unique	O
NIS	O
mutation	O
to	O
identify	O
patients	O
with	O
congenital	B-Disease
hypothyroidism	I-Disease
due	O
to	O
an	O
iodide	B-Disease
transport	I-Disease
defect	I-Disease
in	O
this	O
family	O
and	O
to	O
determine	O
the	O
carrier	O
state	O
of	O
potential	O
parents	O
for	O
genetic	O
counseling	O
and	O
arranging	O
rapid	O
and	O
early	O
diagnosis	O
of	O
their	O
infants	O
.	O

Familial	B-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	I-Disease
(	O
FNDI	B-Disease
)	O
is	O
an	O
inherited	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
hormone	I-Disease
arginine	I-Disease
vasopressin	I-Disease
(	O
AVP	O
)	O
and	O
is	O
transmitted	O
as	O
an	O
autosomal	O
dominant	O
trait	O
.	O

Identification	O
of	O
the	O
molecular	O
defect	O
underlying	O
FNDI	B-Disease
in	O
affected	O
families	O
is	O
a	O
powerful	O
tool	O
for	O
early	O
asymptomatic	O
diagnosis	O
in	O
infants	O
.	O
.	O

Friedreich	B-Disease
ataxia	I-Disease
(	O
FRDA	B-Disease
)	O
,	O
the	O
most	O
common	O
of	O
the	O
inherited	B-Disease
ataxias	I-Disease
,	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
degenerative	I-Disease
disorder	I-Disease
,	O
characterized	O
clinically	O
by	O
onset	O
before	O
the	O
age	O
of	O
25	O
of	O
progressive	B-Disease
gait	I-Disease
and	I-Disease
limb	I-Disease
ataxia	I-Disease
,	O
absence	B-Disease
of	I-Disease
deep	I-Disease
tendon	I-Disease
reflexes	I-Disease
,	O
extensor	B-Disease
plantar	I-Disease
responses	I-Disease
,	O
and	O
loss	B-Disease
of	I-Disease
position	I-Disease
and	I-Disease
vibration	I-Disease
sense	I-Disease
in	O
the	O
lower	O
limbs	O
.	O

The	O
FRDA	B-Disease
gene	O
encodes	O
a	O
widely	O
expressed	O
210	O
-	O
aa	O
protein	O
,	O
frataxin	O
,	O
which	O
is	O
located	O
in	O
mitochondria	O
and	O
is	O
severely	O
reduced	O
in	O
FRDA	B-Disease
patients	O
.	O

Using	O
phosphorus	O
magnetic	O
resonance	O
spectroscopy	O
we	O
demonstrated	O
a	O
maximum	O
rate	O
of	O
muscle	O
mitochondrial	O
ATP	O
production	O
(	O
V	O
(	O
max	O
)	O
)	O
below	O
the	O
normal	O
range	O
in	O
all	O
12	O
FRDA	B-Disease
patients	O
and	O
a	O
strong	O
negative	O
correlation	O
between	O
mitochondrial	O
V	O
(	O
max	O
)	O
and	O
the	O
number	O
of	O
GAA	O
repeats	O
in	O
the	O
smaller	O
allele	O
.	O

Identification	O
of	O
a	O
novel	O
R21X	O
mutation	O
in	O
the	O
liver	O
-	O
type	O
arginase	O
gene	O
(	O
ARG1	O
)	O
in	O
four	O
Portuguese	O
patients	O
with	O
argininemia	B-Disease
.	O

In	O
order	O
to	O
investigate	O
the	O
molecular	O
basis	O
for	O
argininemia	B-Disease
in	O
four	O
unrelated	O
Portuguese	O
patients	O
(	O
two	O
from	O
northern	O
Portugal	O
and	O
two	O
from	O
Madeira	O
Island	O
)	O
we	O
performed	O
a	O
DNA	O
sequence	O
analysis	O
of	O
all	O
the	O
exons	O
and	O
exon	O
/	O
intron	O
boundaries	O
of	O
the	O
liver	O
-	O
type	O
arginase	O
gene	O
(	O
ARG1	O
)	O
.	O

OBJECTIVES	O
A	O
Japanese	O
family	O
with	O
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
(	O
CTX	B-Disease
)	O
was	O
investigated	O
for	O
a	O
sequence	O
alteration	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
gene	O
(	O
CYP27	O
)	O
.	O

Clinical	O
and	O
molecular	O
genetic	O
analysis	O
of	O
19	O
Wolfram	B-Disease
syndrome	I-Disease
kindreds	O
demonstrating	O
a	O
wide	O
spectrum	O
of	O
mutations	O
in	O
WFS1	O
.	O

Direct	O
DNA	O
sequencing	O
was	O
done	O
to	O
screen	O
the	O
entire	O
coding	O
region	O
of	O
the	O
WFS1	O
gene	O
in	O
30	O
patients	O
from	O
19	O
British	O
kindreds	O
with	O
Wolfram	B-Disease
syndrome	I-Disease
.	O

Late	O
-	O
onset	O
familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	B-Disease
)	O
:	O
a	O
subset	O
with	O
distinct	O
clinical	O
,	O
demographic	O
,	O
and	O
molecular	O
genetic	O
characteristics	O
.	O

The	O
control	O
group	O
consisted	O
of	O
40	O
consecutive	O
FMF	B-Disease
patients	O
,	O
who	O
arrived	O
at	O
the	O
FMF	B-Disease
clinic	O
for	O
their	O
regular	O
follow	O
-	O
up	O
visit	O
and	O
were	O
40	O
years	O
of	O
age	O
or	O
older	O
at	O
the	O
time	O
of	O
the	O
examination	O
.	O

Only	O
20	O
of	O
4000	O
(	O
0	O
.	O
5	O
%	O
)	O
patients	O
had	O
late	O
-	O
onset	O
FMF	B-Disease
.	O

01	O
,	O
compared	O
to	O
our	O
regular	O
FMF	B-Disease
population	O
.	O

The	O
hereditary	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
syndrome	I-Disease
is	O
associated	O
with	O
a	O
high	O
frequency	O
of	O
BRCA1	O
mutations	O
.	O

We	O
report	O
on	O
a	O
boy	O
with	O
a	O
maternal	B-Disease
uniparental	I-Disease
disomy	I-Disease
for	I-Disease
chromosome	I-Disease
14	I-Disease
(	O
UPD	B-Disease
(	O
14	O
)	O
)	O
.	O

He	O
showed	O
short	B-Disease
stature	I-Disease
,	O
obesity	B-Disease
,	O
mild	O
developmental	B-Disease
delay	I-Disease
,	O
cryptorchidism	B-Disease
,	O
and	O
some	O
mild	O
dysmorphic	B-Disease
features	I-Disease
.	O

After	O
birth	O
he	O
showed	O
hypotonia	B-Disease
with	O
poor	O
sucking	O
,	O
for	O
which	O
gavage	O
feeding	O
was	O
needed	O
.	O

Recurrent	O
middle	B-Disease
ear	I-Disease
infections	I-Disease
,	O
a	O
high	O
pain	O
threshold	O
,	O
and	O
a	O
great	O
skill	O
with	O
jigsaw	O
puzzles	O
were	O
reported	O
.	O

Two	O
years	O
later	O
he	O
was	O
re	O
-	O
examined	O
because	O
we	O
thought	O
his	O
features	O
fitted	O
the	O
PWS	B-Disease
-	O
like	O
phenotype	O
associated	O
with	O
maternal	O
UPD	B-Disease
(	O
14	O
)	O
.	O

In	O
all	O
the	O
previously	O
described	O
11	O
cases	O
with	O
maternal	O
UPD	B-Disease
(	O
14	O
)	O
,	O
a	O
Robertsonian	O
translocation	O
involving	O
chromosome	O
14	O
was	O
detected	O
cytogenetically	O
before	O
DNA	O
analysis	O
.	O

This	O
finding	O
underlines	O
the	O
importance	O
of	O
DNA	O
analysis	O
for	O
maternal	O
UPD	O
(	O
14	O
)	O
in	O
patients	O
with	O
a	O
similar	O
PWS	B-Disease
-	O
like	O
phenotype	O
even	O
without	O
previous	O
identification	O
of	O
a	O
Robertsonian	O
translocation	O
involving	O
chromosome	O
14	O
.	O
.	O

Friedreich	B-Disease
ataxia	I-Disease
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
caused	O
by	O
mutations	O
in	O
the	O
FRDA	B-Disease
gene	O
that	O
encodes	O
a	O
210	O
-	O
amino	O
acid	O
protein	O
called	O
frataxin	O
.	O

There	O
was	O
no	O
significant	O
correlation	O
between	O
the	O
size	O
of	O
the	O
smaller	O
allele	O
and	O
cardiomyopathy	B-Disease
,	O
diabetes	B-Disease
mellitus	I-Disease
,	O
loss	B-Disease
of	I-Disease
proprioception	I-Disease
,	O
or	O
bladder	B-Disease
symptoms	I-Disease
.	O

The	O
duration	O
of	O
disease	O
is	O
correlated	O
with	O
wheelchair	O
use	O
and	O
the	O
presence	O
of	O
diabetes	B-Disease
,	O
scoliosis	B-Disease
,	O
bladder	B-Disease
symptoms	I-Disease
and	O
impaired	B-Disease
proprioception	I-Disease
,	O
and	O
vibration	O
sense	O
but	O
no	O
other	O
complications	O
studied	O
.	O
.	O

Juvenile	B-Disease
retinoschisis	I-Disease
is	O
an	O
X	B-Disease
-	I-Disease
linked	I-Disease
recessive	I-Disease
disease	I-Disease
caused	O
by	O
mutations	O
in	O
the	O
XLRS1	O
gene	O
.	O

Growth	O
hormone	O
treatment	O
increases	O
CO	O
(	O
2	O
)	O
response	O
,	O
ventilation	O
and	O
central	O
inspiratory	O
drive	O
in	O
children	O
with	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
.	O

CONCLUSION	O
Treatment	O
of	O
children	O
with	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
seems	O
to	O
have	O
a	O
stimulatory	O
effect	O
on	O
central	O
respiratory	O
structures	O
.	O

G130V	O
,	O
a	O
common	O
FRDA	B-Disease
point	O
mutation	O
,	O
appears	O
to	O
have	O
arisen	O
from	O
a	O
common	O
founder	O
.	O

G130V	O
,	O
when	O
present	O
with	O
an	O
expanded	O
GAA	O
repeat	O
on	O
the	O
other	O
allele	O
,	O
is	O
associated	O
with	O
an	O
atypical	O
FRDA	B-Disease
phenotype	O
.	O

Constitutional	O
von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	I-Disease
(	O
VHL	B-Disease
)	O
gene	O
deletions	O
detected	O
in	O
VHL	B-Disease
families	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O

The	O
VHL	B-Disease
gene	O
was	O
localized	O
to	O
chromosome	O
3p25	O
-	O
26	O
and	O
cloned	O
[	O
F	O
.	O
Latif	O
et	O
al	O
.	O
,	O
Science	O
(	O
Washington	O
DC	O
)	O
,	O
260	O
1317	O
-	O
1320	O
,	O
1993	O
]	O
.	O

The	O
reported	O
frequency	O
of	O
detection	O
of	O
VHL	B-Disease
germline	O
mutations	O
has	O
varied	O
from	O
39	O
to	O
80	O
%	O
(	O
J	O
.	O
M	O
.	O
Whaley	O
et	O
al	O
.	O
,	O
Am	O
.	O
J	O
.	O
Hum	O
.	O
Genet	O
.	O
,	O
55	O
1092	O
-	O
1102	O
,	O
1994	O
;	O
Clinical	O
Research	O
Group	O
for	O
Japan	O
,	O
Hum	O
.	O
Mol	O
.	O
Genet	O
.	O
,	O
4	O
2233	O
-	O
2237	O
,	O
1995	O
;	O
F	O
.	O
Chen	O
et	O
al	O
.	O
,	O
Hum	O
.	O
Mutat	O
.	O
,	O
5	O
66	O
-	O
75	O
,	O
1995	O
;	O
E	O
.	O
R	O
.	O
Maher	O
et	O
al	O
.	O
,	O
J	O
.	O
Med	O
.	O
Genet	O
.	O
,	O
33	O
328	O
-	O
332	O
,	O
1996	O
;	O
B	O
.	O
Zbar	O
,	O
Cancer	O
Surv	O
.	O
,	O
25	O
219	O
-	O
232	O
,	O
1995	O
)	O
.	O

We	O
reexamined	O
a	O
group	O
of	O
VHL	B-Disease
patients	O
shown	O
previously	O
by	O
single	O
-	O
strand	O
conformation	O
and	O
sequencing	O
analysis	O
not	O
to	O
harbor	O
point	O
mutations	O
in	O
the	O
VHL	B-Disease
locus	O
.	O

We	O
then	O
tested	O
six	O
phenotypically	O
normal	O
offspring	O
from	O
four	O
of	O
these	O
VHL	B-Disease
families	O
two	O
were	O
found	O
to	O
carry	O
the	O
deletion	O
and	O
the	O
other	O
four	O
were	O
deletion	O
-	O
free	O
.	O

In	O
sum	O
,	O
FISH	O
was	O
found	O
to	O
be	O
a	O
simple	O
and	O
reliable	O
method	O
to	O
detect	O
VHL	B-Disease
germline	O
deletions	O
and	O
practically	O
useful	O
in	O
cases	O
where	O
other	O
methods	O
of	O
screening	O
have	O
failed	O
to	O
detect	O
a	O
VHL	B-Disease
gene	I-Disease
abnormality	I-Disease

The	O
hSNF5	O
/	O
INI1	O
gene	O
which	O
encodes	O
a	O
member	O
of	O
the	O
SWI	O
/	O
SNF	O
chromatin	O
ATP	O
-	O
dependent	O
remodeling	O
complex	O
,	O
is	O
a	O
new	O
tumor	B-Disease
suppressor	O
gene	O
localized	O
on	O
chromosome	O
22q11	O
.	O

We	O
have	O
searched	O
for	O
hSNF5	O
/	O
INI1	O
mutations	O
in	O
229	O
tumors	B-Disease
of	O
various	O
origins	O
using	O
a	O
screening	O
method	O
based	O
on	O
denaturing	O
high	O
-	O
performance	O
liquid	O
chromatography	O
.	O

Recurrent	O
hSNF5	O
/	O
INI1	O
alterations	O
were	O
also	O
observed	O
in	O
choroid	B-Disease
plexus	I-Disease
carcinomas	I-Disease
and	O
in	O
a	O
subset	O
of	O
central	O
primitive	O
neuroectodermal	B-Disease
tumors	I-Disease
(	O
cPNETs	O
)	O
and	O
medulloblastomas	B-Disease
.	O

These	O
results	O
suggest	O
that	O
rhabdoid	B-Disease
tumors	I-Disease
,	O
choroid	B-Disease
plexus	I-Disease
carcinomas	I-Disease
and	O
a	O
subset	O
of	O
medulloblastomas	B-Disease
and	O
cPNETs	O
share	O
common	O
pathways	O
of	O
oncogenesis	O
related	O
to	O
hSNF5	O
/	O
INI1	O
alteration	O
and	O
that	O
hSNF5	O
/	O
INI1	O
mutations	O
define	O
a	O
genetically	O
homogeneous	O
family	O
of	O
highly	O
aggressive	O
cancers	B-Disease
mainly	O
occurring	O
in	O
young	O
children	O
and	O
frequently	O
,	O
but	O
not	O
always	O
,	O
exhibiting	O
a	O
rhabdoid	B-Disease
phenotype	O

Experimental	O
models	O
of	O
polyglutamine	B-Disease
disease	I-Disease
implicate	O
the	O
nucleus	O
in	O
pathogenesis	O
;	O
however	O
,	O
the	O
link	O
between	O
intranuclear	O
expression	O
of	O
expanded	O
polyglutamine	O
and	O
neuronal	B-Disease
dysfunction	I-Disease
remains	O
unclear	O
.	O

These	O
data	O
suggest	O
that	O
an	O
early	O
event	O
in	O
the	O
pathogenesis	O
of	O
SCA3	B-Disease
/	O
MJD	B-Disease
may	O
be	O
an	O
altered	O
conformation	O
of	O
ataxin	O
-	O
3	O
within	O
the	O
nucleus	O
that	O
exposes	O
the	O
polyglutamine	O
domain	O
.	O
.	O

Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
is	O
a	O
complex	O
neurogenetic	B-Disease
disorder	I-Disease
.	O

Four	O
mouse	O
models	O
of	O
PWS	B-Disease
have	O
been	O
reported	O
but	O
these	O
do	O
not	O
definitively	O
allow	O
the	O
delineation	O
of	O
the	O
critical	O
region	O
and	O
the	O
associated	O
genes	O
involved	O
in	O
the	O
aetiology	O
of	O
PWS	B-Disease
.	O

Therefore	O
,	O
the	O
isolation	O
of	O
new	O
genes	O
in	O
this	O
region	O
remains	O
crucial	O
for	O
a	O
better	O
understanding	O
of	O
the	O
molecular	O
basis	O
of	O
PWS	B-Disease
.	O

Alveolar	B-Disease
rhabdomyosarcoma	I-Disease
is	O
an	O
aggressive	O
pediatric	B-Disease
cancer	I-Disease
of	I-Disease
striated	I-Disease
muscle	I-Disease
characterized	O
in	O
60	O
%	O
of	O
cases	O
by	O
a	O
t	O
(	O
2	O
;	O
13	O
)	O
(	O
q35	O
;	O
q14	O
)	O
.	O

Experimental	O
hemochromatosis	B-Disease
due	O
to	O
MHC	O
class	O
I	O
HFE	B-Disease
deficiency	I-Disease
:	O
immune	O
status	O
and	O
iron	O
metabolism	O
.	O

HFE	B-Disease
-	I-Disease
deficient	I-Disease
animals	O
were	O
analyzed	O
for	O
a	O
comprehensive	O
set	O
of	O
metabolic	O
and	O
immune	O
parameters	O
.	O

Ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
is	O
a	O
rare	O
genetic	B-Disease
disorder	I-Disease
associated	O
with	O
immune	B-Disease
deficiency	I-Disease
,	O
chromosome	B-Disease
instability	I-Disease
,	O
and	O
a	O
predisposition	O
to	O
lymphoid	B-Disease
malignancy	I-Disease
.	O

Chromosomes	O
of	O
lymphocytes	O
from	O
one	O
of	O
the	O
patients	O
were	O
studied	O
before	O
and	O
after	O
the	O
onset	O
of	O
chronic	B-Disease
lymphocytic	I-Disease
leukemia	I-Disease
.	O

This	O
clone	O
appears	O
to	O
have	O
given	O
rise	O
to	O
the	O
leukemic	B-Disease
cells	O
.	O

Increasing	O
evidence	O
,	O
provided	O
by	O
others	O
,	O
for	O
the	O
nonrandom	O
involvement	O
of	O
14q	O
in	O
African	O
-	O
type	O
Burkitts	B-Disease
lymphoma	I-Disease
and	O
other	O
lymphoid	B-Disease
neoplasms	I-Disease
further	O
strengthens	O
this	O
hypothesis	O
.	O
.	O

We	O
report	O
new	O
mutations	O
in	O
exon	O
9	O
of	O
the	O
WT1	O
gene	O
that	O
did	O
not	O
alter	O
the	O
ratio	O
of	O
+	O
/	O
-	O
KTS	O
splice	O
isoforms	O
in	O
two	O
unrelated	O
patients	O
with	O
Frasier	B-Disease
syndrome	I-Disease
(	O
FS	B-Disease
)	O
.	O

The	O
results	O
suggest	O
that	O
the	O
two	O
syndromes	O
originate	O
from	O
the	O
same	O
WT1	B-Disease
gene	I-Disease
abnormality	I-Disease
.	O

Splice	O
-	O
site	O
mutation	O
in	O
the	O
PDS	B-Disease
gene	O
may	O
result	O
in	O
intrafamilial	O
variability	O
for	O
deafness	B-Disease
in	O
Pendred	B-Disease
syndrome	I-Disease
.	O

This	O
disorder	O
may	O
account	O
for	O
up	O
to	O
10	O
%	O
of	O
cases	O
of	O
hereditary	B-Disease
deafness	I-Disease
.	O

We	O
performed	O
mutation	O
analysis	O
of	O
individual	O
exons	O
of	O
the	O
PDS	B-Disease
gene	O
in	O
one	O
Spanish	O
family	O
that	O
shows	O
intrafamilial	O
variability	O
of	O
the	O
deafness	B-Disease
phenotype	O
(	O
two	O
patients	O
with	O
profound	O
and	O
one	O
with	O
moderate	O
-	O
severe	O
deafness	B-Disease
)	O
.	O

Since	O
the	O
newly	O
created	O
donor	O
splice	O
site	O
is	O
likely	O
to	O
compete	O
with	O
the	O
normal	O
one	O
,	O
variations	O
of	O
the	O
levels	O
of	O
normal	O
and	O
aberrant	O
transcripts	O
of	O
the	O
PDS	B-Disease
gene	O
in	O
the	O
cochlea	O
may	O
explain	O
the	O
variability	O
in	O
the	O
deafness	B-Disease
presentation	O
.	O
.	O

Sjogren	B-Disease
-	I-Disease
Larsson	I-Disease
syndrome	I-Disease
(	O
SLS	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
characterized	O
by	O
ichthyosis	B-Disease
,	O
mental	B-Disease
retardation	I-Disease
,	O
spasticity	B-Disease
,	O
and	O
deficient	B-Disease
activity	I-Disease
of	I-Disease
fatty	I-Disease
aldehyde	I-Disease
dehydrogenase	I-Disease
(	O
FALDH	O
)	O
.	O

All	O
of	O
the	O
patients	O
with	O
SLS	B-Disease
were	O
found	O
to	O
carry	O
mutations	O
.	O

Our	O
results	O
demonstrate	O
that	O
SLS	B-Disease
is	O
caused	O
by	O
a	O
strikingly	O
heterogeneous	O
group	O
of	O
mutations	O
in	O
the	O
FALDH	O
gene	O
and	O
provide	O
a	O
framework	O
for	O
understanding	O
the	O
genetic	O
basis	O
of	O
SLS	B-Disease
and	O
the	O
development	O
of	O
DNA	O
-	O
based	O
diagnostic	O
tests	O
.	O
.	O

Papillon	B-Disease
-	I-Disease
Lefevre	I-Disease
syndrome	I-Disease
,	O
or	O
keratosis	B-Disease
palmoplantaris	I-Disease
with	O
periodontopathia	B-Disease
(	O
PLS	B-Disease
,	O
MIM	O
245000	O
)	O
,	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
that	O
is	O
mainly	O
ascertained	O
by	O
dentists	O
because	O
of	O
the	O
severe	O
periodontitis	B-Disease
that	O
afflicts	O
patients	O
.	O

Palmoplantar	B-Disease
keratosis	I-Disease
,	O
varying	O
from	O
mild	O
psoriasiform	O
scaly	O
skin	O
to	O
overt	O
hyperkeratosis	B-Disease
,	O
typically	O
develops	O
within	O
the	O
first	O
three	O
years	O
of	O
life	O
.	O

Most	O
PLS	B-Disease
patients	O
display	O
both	O
periodontitis	B-Disease
and	O
hyperkeratosis	B-Disease
.	O

In	O
two	O
of	O
these	O
families	O
we	O
used	O
a	O
functional	O
assay	O
to	O
demonstrate	O
an	O
almost	O
total	O
loss	O
of	O
cathepsin	O
C	O
activity	O
in	O
PLS	B-Disease
patients	O
and	O
reduced	O
activity	O
in	O
obligate	O
carriers	O
.	O

Van	B-Disease
der	I-Disease
Woude	I-Disease
syndrome	I-Disease
(	O
VWS	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
craniofacial	I-Disease
disorder	I-Disease
with	O
high	O
penetrance	O
and	O
variable	O
expression	O
.	O

All	O
VWS	B-Disease
families	O
studied	O
to	O
date	O
map	O
the	O
disease	O
gene	O
to	O
a	O
<	O
2	O
cM	O
region	O
of	O
chromosome	O
1q32	O
,	O
with	O
no	O
evidence	O
of	O
locus	O
heterogeneity	O
.	O

We	O
analyzed	O
four	O
multiplex	O
VWS	B-Disease
families	O
.	O

Our	O
assay	O
method	O
for	O
short	O
tandem	O
repeat	O
(	O
STR	O
)	O
markers	O
provided	O
highly	O
accurate	O
size	O
estimation	O
of	O
marker	O
allele	O
fragment	O
sizes	O
,	O
and	O
therefore	O
enabled	O
us	O
to	O
determine	O
the	O
specific	O
alleles	O
segregating	O
with	O
the	O
VWS	B-Disease
gene	O
in	O
each	O
of	O
our	O
four	O
families	O
.	O

These	O
results	O
suggest	O
the	O
possibility	O
of	O
a	O
unique	O
origin	O
for	O
a	O
mutation	O
responsible	O
for	O
many	O
or	O
most	O
cases	O
of	O
VWS	B-Disease
.	O

Mutations	O
of	O
the	O
cathepsin	O
C	O
gene	O
are	O
responsible	O
for	O
Papillon	B-Disease
-	I-Disease
Lefevre	I-Disease
syndrome	I-Disease
.	O

A	O
major	O
gene	O
locus	O
for	O
PLS	B-Disease
has	O
been	O
mapped	O
to	O
a	O
2	O
.	O

Sequence	O
analysis	O
of	O
CTSC	O
from	O
subjects	O
affected	O
with	O
PLS	B-Disease
from	O
five	O
consanguineous	O
Turkish	O
families	O
identified	O
four	O
different	O
mutations	O
.	O

Parents	O
and	O
sibs	O
heterozygous	O
for	O
cathepsin	O
C	O
mutations	O
do	O
not	O
show	O
either	O
the	O
palmoplantar	B-Disease
hyperkeratosis	I-Disease
or	O
severe	O
early	O
onset	O
periodontitis	B-Disease
characteristic	O
of	O
PLS	B-Disease
.	O

Mutational	O
analysis	O
of	O
the	O
HGO	O
gene	O
in	O
Finnish	O
alkaptonuria	B-Disease
patients	O
.	O

So	O
far	O
17	O
mutations	O
have	O
been	O
characterised	O
in	O
AKU	B-Disease
patients	O
of	O
different	O
ethnic	O
origin	O
.	O

The	O
three	O
novel	O
AKU	B-Disease
mutations	O
are	O
most	O
likely	O
specific	O
for	O
the	O
Finnish	O
population	O
and	O
have	O
originated	O
recently	O
.	O
.	O

Inherited	O
mutations	O
of	O
the	O
APC	B-Disease
gene	O
predispose	O
carriers	O
to	O
multiple	O
adenomatous	B-Disease
polyps	I-Disease
of	I-Disease
the	I-Disease
colon	I-Disease
and	I-Disease
rectum	I-Disease
and	O
to	O
colorectal	B-Disease
cancer	I-Disease
.	O

Many	O
individuals	O
with	O
AAPC	B-Disease
develop	O
relatively	O
few	O
colorectal	B-Disease
polyps	I-Disease
but	O
are	O
still	O
at	O
high	O
risk	O
for	O
colorectal	B-Disease
cancer	I-Disease
.	O

This	O
disease	O
-	O
causing	O
mutation	O
is	O
a	O
single	O
basepair	O
change	O
(	O
G	O
to	O
A	O
)	O
in	O
the	O
splice	O
-	O
acceptor	O
region	O
of	O
APC	B-Disease
intron	O
3	O
that	O
creates	O
a	O
mutant	O
RNA	O
without	O
exon	O
4	O
of	O
APC	O
.	O

Furthermore	O
,	O
the	O
identification	O
of	O
this	O
germline	O
mutation	O
strengthens	O
the	O
correlation	O
between	O
the	O
5	O
location	O
of	O
an	O
APC	B-Disease
disease	O
-	O
causing	O
mutation	O
and	O
the	O
attenuated	B-Disease
polyposis	I-Disease
phenotype	O
.	O
.	O

Alstrom	B-Disease
syndrome	I-Disease
is	O
a	O
rare	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
characterized	O
by	O
retinal	B-Disease
degeneration	I-Disease
,	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
,	O
early	O
-	O
onset	O
obesity	B-Disease
,	O
and	O
non	B-Disease
-	I-Disease
insulin	I-Disease
-	I-Disease
dependent	I-Disease
diabetes	I-Disease
mellitus	I-Disease
.	O

To	O
confirm	O
these	O
findings	O
,	O
a	O
large	O
linkage	O
study	O
was	O
performed	O
in	O
twelve	O
additional	O
families	O
segregating	O
for	O
Alstrom	B-Disease
syndrome	I-Disease
.	O

Pendred	B-Disease
syndrome	I-Disease
comprises	O
congenital	B-Disease
sensorineural	I-Disease
hearing	I-Disease
loss	I-Disease
,	O
thyroid	B-Disease
goiter	I-Disease
,	O
and	O
positive	O
perchlorate	O
discharge	O
test	O
.	O

Molecular	O
analysis	O
of	O
the	O
PDS	B-Disease
gene	O
was	O
performed	O
in	O
two	O
consanguineous	O
large	O
families	O
from	O
Southern	O
Tunisia	O
comprising	O
a	O
total	O
of	O
23	O
individuals	O
affected	O
with	O
profound	O
congenital	B-Disease
deafness	I-Disease
;	O
the	O
same	O
missense	O
mutation	O
,	O
L445W	O
,	O
was	O
identified	O
in	O
all	O
affected	O
individuals	O
.	O

In	O
contrast	O
,	O
goiter	B-Disease
was	O
present	O
in	O
only	O
11	O
affected	O
individuals	O
,	O
who	O
interestingly	O
had	O
a	O
normal	O
result	O
of	O
the	O
perchlorate	O
discharge	O
test	O
whenever	O
performed	O
.	O

Knobloch	B-Disease
syndrome	I-Disease
involving	O
midline	B-Disease
scalp	I-Disease
defect	I-Disease
of	I-Disease
the	I-Disease
frontal	I-Disease
region	I-Disease
.	O

He	O
has	O
vitreoretinal	B-Disease
degeneration	I-Disease
,	O
high	B-Disease
myopia	I-Disease
,	O
cataract	B-Disease
,	O
telecanthus	B-Disease
,	O
hypertelorism	B-Disease
,	O
and	O
a	O
high	B-Disease
-	I-Disease
arched	I-Disease
palate	I-Disease
.	O

Our	O
patient	O
illustrates	O
the	O
importance	O
of	O
investigating	O
for	O
underlying	O
ocular	O
and	O
central	O
nervous	O
system	O
pathology	O
whenever	O
midline	B-Disease
scalp	I-Disease
defects	I-Disease
are	O
present	O
.	O
.	O

We	O
show	O
that	O
hypomorphic	O
mutations	O
in	O
hMRE11	O
,	O
but	O
not	O
in	O
ATM	O
,	O
are	O
present	O
in	O
certain	O
individuals	O
with	O
an	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
-	I-Disease
like	I-Disease
disorder	I-Disease
(	O
ATLD	B-Disease
)	O
.	O

These	O
data	O
demonstrate	O
that	O
ATM	O
and	O
the	O
hMre11	O
/	O
hRad50	O
/	O
Nbs1	O
protein	O
complex	O
act	O
in	O
the	O
same	O
DNA	O
damage	O
response	O
pathway	O
and	O
link	O
hMre11	O
to	O
the	O
complex	O
pathology	O
of	O
A	B-Disease
-	I-Disease
T	I-Disease
.	O
.	O

Familial	B-Disease
expansile	I-Disease
osteolysis	I-Disease
(	O
FEO	B-Disease
,	O
MIM	O
174810	O
)	O
is	O
a	O
rare	O
,	O
autosomal	B-Disease
dominant	I-Disease
bone	I-Disease
disorder	I-Disease
characterized	O
by	O
focal	O
areas	O
of	O
increased	B-Disease
bone	I-Disease
remodelling	I-Disease
.	O

Our	O
previous	O
linkage	O
studies	O
mapped	O
the	O
gene	O
responsible	O
for	O
FEO	B-Disease
to	O
an	O
interval	O
of	O
less	O
than	O
5	O
cM	O
between	O
D18S64	O
and	O
D18S51	O
on	O
chromosome	O
18q21	O
.	O

Cardiac	O
Na	O
(	O
+	O
)	O
channel	O
dysfunction	O
in	O
Brugada	B-Disease
syndrome	I-Disease
is	O
aggravated	O
by	O
beta	O
(	O
1	O
)	O
-	O
subunit	O
.	O

Here	O
,	O
we	O
characterize	O
the	O
altered	O
effects	O
of	O
a	O
human	O
beta	O
(	O
1	O
)	O
-	O
subunit	O
(	O
hbeta	O
(	O
1	O
)	O
)	O
on	O
the	O
heterologously	O
expressed	O
hH1	O
mutation	O
(	O
T1620M	O
)	O
previously	O
associated	O
with	O
IVF	B-Disease
.	O

CONCLUSIONS	O
It	O
is	O
suggested	O
that	O
coexpression	O
of	O
hbeta	O
(	O
1	O
)	O
exposes	O
a	O
more	O
severe	O
functional	O
defect	O
that	O
results	O
in	O
a	O
greater	O
overlap	O
in	O
the	O
relationship	O
between	O
channel	O
inactivation	O
and	O
activation	O
(	O
window	O
current	O
)	O
in	O
T1620M	O
,	O
which	O
is	O
proposed	O
to	O
be	O
a	O
potential	O
pathophysiological	O
mechanism	O
of	O
IVF	B-Disease
in	O
vivo	O
.	O

In	O
hereditary	B-Disease
retinoblastoma	I-Disease
,	O
different	O
epidemiological	O
studies	O
have	O
indicated	O
a	O
preferential	O
paternal	O
transmission	O
of	O
mutant	O
retinoblastoma	B-Disease
alleles	O
to	O
offspring	O
,	O
suggesting	O
the	O
occurrence	O
of	O
a	O
meiotic	O
drive	O
.	O

Single	O
-	O
sperm	O
typing	O
techniques	O
were	O
performed	O
for	O
each	O
sample	O
by	O
study	O
of	O
two	O
informative	O
short	O
tandem	O
repeats	O
located	O
either	O
in	O
or	O
close	O
to	O
the	O
retinoblastoma	B-Disease
gene	O
(	O
RB1	O
)	O
.	O

Friedreich	B-Disease
ataxia	I-Disease
,	O
an	O
autosomal	B-Disease
recessive	I-Disease
neurodegenerative	I-Disease
disease	I-Disease
,	O
is	O
the	O
most	O
common	O
of	O
the	O
inherited	B-Disease
ataxias	I-Disease
.	O

There	O
is	O
mounting	O
evidence	O
to	O
suggest	O
that	O
Friedreich	B-Disease
ataxia	I-Disease
is	O
the	O
result	O
of	O
accumulation	O
of	O
iron	O
in	O
mitochondria	O
leading	O
to	O
excess	O
production	O
of	O
free	O
radicals	O
,	O
which	O
then	O
results	O
in	O
cellular	O
damage	O
and	O
death	O
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
retinoschisis	I-Disease
with	O
point	O
mutations	O
in	O
the	O
XLRS1	O
gene	O
.	O

OBJECTIVE	O
To	O
analyze	O
Japanese	O
patients	O
clinically	O
diagnosed	O
as	O
having	O
XLRS	B-Disease
formutational	O
changes	O
in	O
the	O
XLRS1	O
gene	O
.	O

CONCLUSIONS	O
The	O
discovery	O
of	O
new	O
point	O
mutations	O
in	O
this	O
study	O
increases	O
the	O
available	O
information	O
regarding	O
the	O
spectrum	O
of	O
genetic	B-Disease
abnormalities	I-Disease
and	O
clinical	O
manifestations	O
of	O
XLRS	B-Disease
.	O

Ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
is	O
a	O
hereditary	B-Disease
multisystemic	I-Disease
disease	I-Disease
resulting	O
from	O
mutations	O
of	O
ataxia	B-Disease
telangiectasia	I-Disease
,	O
mutated	O
(	O
ATM	O
)	O
and	O
is	O
characterized	O
by	O
neurodegeneration	B-Disease
,	O
cancer	B-Disease
,	O
immune	B-Disease
defects	I-Disease
,	O
and	O
hypersensitivity	B-Disease
to	I-Disease
ionizing	I-Disease
radiation	I-Disease
.	O

Haim	B-Disease
-	I-Disease
Munk	I-Disease
syndrome	I-Disease
and	O
Papillon	B-Disease
-	I-Disease
Lefevre	I-Disease
syndrome	I-Disease
are	O
allelic	O
mutations	O
in	O
cathepsin	O
C	O
.	O

Although	O
both	O
PLS	B-Disease
and	O
HMS	B-Disease
share	O
the	O
cardinal	O
features	O
of	O
PPK	B-Disease
and	O
severe	O
periodontitis	B-Disease
,	O
a	O
number	O
of	O
additional	O
findings	O
are	O
reported	O
in	O
HMS	B-Disease
including	O
arachnodactyly	B-Disease
,	O
acro	B-Disease
-	I-Disease
osteolysis	I-Disease
,	O
atrophic	B-Disease
changes	I-Disease
of	I-Disease
the	I-Disease
nails	I-Disease
,	O
and	O
a	O
radiographic	B-Disease
deformity	I-Disease
of	I-Disease
the	I-Disease
fingers	I-Disease
.	O

Although	O
autosomal	O
recessive	O
transmission	O
of	O
PLS	B-Disease
is	O
evident	O
,	O
a	O
more	O
"	O
complex	O
"	O
autosomal	O
recessive	O
pattern	O
of	O
inheritance	O
with	O
phenotypic	O
influences	O
from	O
a	O
closely	O
linked	O
modifying	O
locus	O
has	O
been	O
hypothesised	O
for	O
HMS	B-Disease
.	O

To	O
determine	O
if	O
a	O
cathepsin	O
C	O
mutation	O
is	O
also	O
responsible	O
for	O
HMS	B-Disease
,	O
we	O
sequenced	O
the	O
gene	O
in	O
affected	O
and	O
unaffected	O
subjects	O
from	O
the	O
Cochin	O
isolate	O
in	O
which	O
both	O
the	O
PLS	B-Disease
and	O
HMS	B-Disease
phenotypes	O
appear	O
.	O

This	O
finding	O
supports	O
simple	O
autosomal	O
recessive	O
inheritance	O
for	O
HMS	B-Disease
in	O
these	O
families	O
.	O

These	O
findings	O
provide	O
evidence	O
that	O
PLS	B-Disease
and	O
HMS	B-Disease
are	O
allelic	O
variants	O
of	O
cathepsin	O
C	O
gene	O
mutations	O
.	O
.	O

Mutations	O
in	O
the	O
ATM	O
gene	O
are	O
responsible	O
for	O
the	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
A	B-Disease
-	I-Disease
T	I-Disease
)	O
(	O
MIM	O
208900	O
)	O
.	O

In	O
view	O
of	O
this	O
discrepancy	O
,	O
we	O
examined	O
the	O
frequency	O
of	O
ATM	O
germline	O
mutations	O
in	O
a	O
selected	O
group	O
of	O
Dutch	O
patients	O
with	O
breast	B-Disease
cancer	I-Disease
.	O

The	O
82	O
patients	O
included	O
in	O
this	O
study	O
had	O
developed	O
breast	B-Disease
cancer	I-Disease
at	O
age	O
<	O
45	O
and	O
had	O
survived	O
>	O
/	O
=	O
5	O
years	O
(	O
mean	O
15	O
years	O
)	O
,	O
and	O
in	O
33	O
(	O
40	O
%	O
)	O
of	O
the	O
patients	O
a	O
contralateral	O
breast	O
tumor	O
had	O
been	O
diagnosed	O
.	O

From	O
the	O
alignment	O
of	O
the	O
amino	O
acid	O
(	O
aa	O
)	O
sequence	O
of	O
52	O
glucose	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
species	O
from	O
42	O
different	O
organisms	O
,	O
we	O
found	O
a	O
striking	O
correlation	O
between	O
the	O
aa	O
replacements	O
that	O
cause	O
G6PD	B-Disease
deficiency	I-Disease
in	O
humans	O
and	O
the	O
sequence	O
conservation	O
of	O
G6PD	O
two	O
-	O
thirds	O
of	O
such	O
replacements	O
are	O
in	O
highly	O
and	O
moderately	O
conserved	O
(	O
50	O
-	O
99	O
%	O
)	O
aa	O
;	O
relatively	O
few	O
are	O
in	O
fully	O
conserved	O
aa	O
(	O
where	O
they	O
might	O
be	O
lethal	O
)	O
or	O
in	O
poorly	O
conserved	O
aa	O
,	O
where	O
presumably	O
they	O
simply	O
would	O
not	O
cause	O
G6PD	B-Disease
deficiency	I-Disease
.	O

Myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
is	O
the	O
most	O
prevalent	O
inherited	B-Disease
neuromuscular	I-Disease
disease	I-Disease
in	O
adults	O
.	O

Information	O
on	O
DMPK	O
mRNA	O
and	O
protein	O
isoform	O
expression	O
patterns	O
will	O
be	O
useful	O
for	O
recognizing	O
differential	O
effects	O
of	O
(	O
CTG	O
)	O
(	O
n	O
)	O
expansion	O
in	O
DM	B-Disease
manifestation	O
.	O
.	O

Protein	B-Disease
S	I-Disease
deficiency	I-Disease
is	O
a	O
recognized	O
risk	O
factor	O
for	O
venous	B-Disease
thrombosis	I-Disease
.	O

Twenty	O
-	O
eight	O
index	O
patients	O
with	O
protein	B-Disease
S	I-Disease
deficiency	I-Disease
and	O
a	O
PROS1	B-Disease
gene	I-Disease
defect	I-Disease
were	O
studied	O
,	O
together	O
with	O
109	O
first	O
-	O
degree	O
relatives	O
.	O

First	O
-	O
degree	O
relatives	O
with	O
a	O
PROS1	B-Disease
gene	I-Disease
defect	I-Disease
had	O
a	O
5	O
.	O

Although	O
pregnancy	O
/	O
puerperium	O
and	O
immobility	O
/	O
trauma	B-Disease
were	O
important	O
precipitating	O
factors	O
for	O
thrombosis	B-Disease
,	O
almost	O
half	O
of	O
the	O
events	O
were	O
spontaneous	O
.	O

We	O
conclude	O
that	O
persons	O
with	O
PROS1	B-Disease
gene	I-Disease
defects	I-Disease
and	O
protein	B-Disease
S	I-Disease
deficiency	I-Disease
are	O
at	O
increased	O
risk	O
of	O
thrombosis	B-Disease
and	O
that	O
free	O
protein	O
S	O
estimation	O
offers	O
the	O
most	O
reliable	O
way	O
of	O
diagnosing	O
the	O
deficiency	O
.	O

Autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
(	O
ALPS	B-Disease
)	O
is	O
characterized	O
by	O
autoimmune	O
features	O
and	O
lymphoproliferations	O
and	O
is	O
generally	O
caused	O
by	O
defective	O
Fas	O
-	O
mediated	O
apoptosis	O
.	O

The	O
patient	O
reported	O
here	O
is	O
a	O
human	O
homologue	O
of	O
the	O
Fas	O
-	O
null	O
mouse	O
,	O
inasmuch	O
as	O
she	O
carries	O
an	O
autosomal	O
homozygous	O
mutation	O
in	O
the	O
FAS	O
gene	O
and	O
she	O
shows	O
the	O
severe	O
and	O
accelerated	O
ALPS	B-Disease
phenotype	O
.	O

Identification	O
of	O
novel	O
imprinted	O
transcripts	O
in	O
the	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
and	O
Angelman	B-Disease
syndrome	I-Disease
deletion	O
region	O
:	O
further	O
evidence	O
for	O
regional	O
imprinting	O
control	O
.	O

Loss	O
of	O
expression	O
of	O
imprinted	O
,	O
paternally	O
expressed	O
genes	O
has	O
been	O
implicated	O
in	O
PWS	B-Disease
.	O

To	O
identify	O
additional	O
imprinted	O
genes	O
that	O
could	O
contribute	O
to	O
the	O
PWS	B-Disease
phenotype	O
and	O
to	O
understand	O
the	O
regional	O
control	O
of	O
imprinting	O
in	O
15q11	O
-	O
q13	O
,	O
we	O
have	O
constructed	O
an	O
imprinted	O
transcript	O
map	O
of	O
the	O
PWS	O
-	O
AS	O
deletion	O
interval	O
.	O

A	O
previous	O
linkage	O
study	O
provided	O
evidence	O
for	O
a	O
prostate	B-Disease
cancer	I-Disease
-	O
susceptibility	O
locus	O
at	O
1q24	O
-	O
25	O
.	O

The	O
present	O
study	O
describes	O
a	O
combined	O
analysis	O
for	O
six	O
markers	O
in	O
the	O
1q24	O
-	O
25	O
region	O
in	O
772	O
families	O
affected	O
by	O
hereditary	B-Disease
prostate	I-Disease
cancer	I-Disease
and	O
ascertained	O
by	O
the	O
members	O
of	O
the	O
International	O
Consortium	O
for	O
Prostate	B-Disease
Cancer	I-Disease
Genetics	O
(	O
ICPCG	O
)	O
from	O
North	O
America	O
,	O
Australia	O
,	O
Finland	O
,	O
Norway	O
,	O
Sweden	O
,	O
and	O
the	O
United	O
Kingdom	O
.	O

Although	O
HPC1	O
accounts	O
for	O
only	O
a	O
small	O
proportion	O
of	O
all	O
families	O
affected	O
by	O
hereditary	B-Disease
prostate	I-Disease
cancer	I-Disease
,	O
it	O
appears	O
to	O
play	O
a	O
more	O
prominent	O
role	O
in	O
the	O
subset	O
of	O
families	O
with	O
several	O
members	O
affected	O
at	O
an	O
early	O
age	O
and	O
with	O
male	O
-	O
to	O
-	O
male	O
disease	O
transmission	O
.	O

Large	O
intergenerational	O
repeat	O
expansions	O
of	O
the	O
CAG	O
trinucleotide	O
repeat	O
in	O
the	O
HD	B-Disease
gene	O
have	O
been	O
well	O
documented	O
for	O
the	O
male	O
germline	O
.	O

Motor	B-Disease
incoordination	I-Disease
,	O
immune	B-Disease
deficiencies	I-Disease
,	O
and	O
an	O
increased	O
risk	O
of	O
cancer	B-Disease
are	O
the	O
characteristic	O
features	O
of	O
the	O
hereditary	B-Disease
disease	I-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
A	B-Disease
-	I-Disease
T	I-Disease
)	O
,	O
which	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
ATM	O
gene	O
.	O

Atm	O
(	O
y	O
/	O
y	O
)	O
mice	O
exhibit	O
deficits	O
in	O
motor	O
learning	O
indicative	O
of	O
cerebellar	B-Disease
dysfunction	I-Disease
.	O

These	O
findings	O
establish	O
that	O
some	O
neuropathological	B-Disease
abnormalities	I-Disease
seen	O
in	O
A	B-Disease
-	I-Disease
T	I-Disease
patients	O
also	O
are	O
present	O
in	O
Atm	O
mutant	O
mice	O
.	O

We	O
discuss	O
these	O
findings	O
in	O
the	O
context	O
of	O
the	O
hypothesis	O
that	O
abnormal	O
development	O
of	O
Purkinje	O
cells	O
and	O
lymphocytes	O
contributes	O
to	O
the	O
pathogenesis	O
of	O
A	B-Disease
-	I-Disease
T	I-Disease
.	O
.	O

Wilson	B-Disease
disease	I-Disease
(	O
WD	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
characterized	O
by	O
copper	O
accumulation	O
in	O
the	O
liver	O
,	O
brain	O
,	O
kidneys	O
,	O
and	O
corneas	O
,	O
and	O
culminating	O
in	O
copper	O
toxication	O
in	O
these	O
organs	O
.	O

Therefore	O
,	O
the	O
accumulation	O
of	O
the	O
types	O
of	O
mutations	O
in	O
Japanese	O
patients	O
with	O
WD	B-Disease
will	O
facilitate	O
the	O
fast	O
and	O
effective	O
genetic	O
diagnosis	O
of	O
WD	B-Disease
in	O
Japanese	O
patients	O
.	O
.	O

The	O
Rho	O
-	O
family	O
GTPase	O
,	O
Cdc42	O
,	O
can	O
regulate	O
the	O
actin	O
cytoskeleton	O
through	O
activation	O
of	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
protein	O
(	O
WASP	O
)	O
family	O
members	O
.	O

Machado	B-Disease
-	I-Disease
Joseph	I-Disease
disease	I-Disease
(	O
MJD	B-Disease
)	O
belongs	O
to	O
a	O
group	O
of	O
clinically	O
and	O
genetically	O
heterogeneous	O
neurodegenerative	B-Disease
disorders	I-Disease
characterized	O
by	O
progressive	B-Disease
cerebellar	I-Disease
ataxia	I-Disease
.	O

Analyzing	O
the	O
expression	O
level	O
of	O
the	O
SCA3	O
gene	O
in	O
several	O
human	O
brain	O
sections	O
revealed	O
no	O
significant	O
higher	O
mRNA	O
level	O
in	O
regions	O
predominantly	O
affected	O
in	O
MJD	B-Disease
.	O

Emerin	B-Disease
,	I-Disease
deficiency	I-Disease
of	O
which	O
causes	O
Emery	B-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
,	O
is	O
localized	O
at	O
the	O
inner	O
nuclear	O
membrane	O
.	O

The	O
gene	O
for	O
EDMD	B-Disease
on	O
Xq28	O
encodes	O
a	O
novel	O
protein	O
named	O
emerin	O
that	O
localizes	O
at	O
the	O
nuclear	O
membrane	O
of	O
skeletal	O
,	O
cardiac	O
and	O
smooth	O
muscles	O
and	O
some	O
other	O
non	O
-	O
muscle	O
tissues	O
.	O

Friedreich	B-Disease
ataxia	I-Disease
(	O
FRDA	B-Disease
)	O
is	O
the	O
most	O
common	O
form	O
of	O
autosomal	B-Disease
recessive	I-Disease
ataxia	I-Disease
.	O

We	O
now	O
provide	O
strong	O
evidence	O
of	O
a	O
second	O
FRDA	B-Disease
locus	O
.	O

Although	O
the	O
patients	O
studied	O
had	O
typical	O
FRDA	B-Disease
,	O
one	O
sibpair	O
had	O
the	O
uncommon	O
symptom	O
of	O
retained	O
tendon	O
reflexes	O
.	O

The	O
observation	O
of	O
typical	O
mutations	O
in	O
STM7	O
/	O
X25	O
(	O
GAA	O
expansions	O
)	O
in	O
this	O
patient	O
demonstrates	O
that	O
the	O
two	O
genetically	O
different	O
forms	O
of	O
FRDA	B-Disease
cannot	O
be	O
distinguished	O
clinically	O
.	O
.	O

Impaired	B-Disease
glucose	I-Disease
tolerance	I-Disease
(	O
IGT	B-Disease
)	O
and	O
hypertriglyceridemia	B-Disease
are	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
diabetes	B-Disease
mellitus	I-Disease
and	O
cardiovascular	B-Disease
disease	I-Disease
.	O

Family	O
screening	O
in	O
the	O
initial	O
cohort	O
identified	O
18	O
men	O
from	O
five	O
families	O
with	O
severe	O
hyperglycerolemia	B-Disease
(	O
values	O
above	O
2	O
.	O
0	O
mmol	O
/	O
liter	O
)	O
and	O
demonstrated	O
an	O
X	O
-	O
linked	O
pattern	O
of	O
inheritance	O
.	O

Primary	B-Disease
dystonias	I-Disease
are	O
movement	B-Disease
disorders	I-Disease
with	O
dystonia	B-Disease
as	O
a	O
major	O
symptom	O
.	O

1	O
in	O
the	O
X	B-Disease
-	I-Disease
linked	I-Disease
dystonia	I-Disease
parkinsonism	I-Disease
syndrome	I-Disease
and	O
to	O
Xq22	O
in	O
X	B-Disease
-	I-Disease
linked	I-Disease
sensorineural	I-Disease
deafness	I-Disease
,	O
dystonia	B-Disease
,	O
and	O
mental	B-Disease
retardation	I-Disease
.	O

In	O
sensorineural	B-Disease
deafness	I-Disease
,	O
dystonia	B-Disease
,	O
and	O
mental	B-Disease
retardation	I-Disease
,	O
mutations	O
were	O
found	O
in	O
the	O
gene	O
DDP	O
coding	O
for	O
a	O
polypeptide	O
of	O
unknown	O
function	O
.	O

Determination	O
of	O
30	O
X	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
mutations	O
,	O
including	O
15	O
not	O
previously	O
described	O
.	O

Of	O
particular	O
concern	O
are	O
female	O
members	O
of	O
kindreds	O
segregating	O
X	B-Disease
-	I-Disease
ALD	I-Disease
mutations	O
,	O
because	O
normal	O
VLCFA	O
levels	O
do	O
not	O
guarantee	O
lack	O
of	O
carrier	O
status	O
.	O

Using	O
this	O
methodology	O
we	O
have	O
found	O
X	B-Disease
-	I-Disease
ALD	I-Disease
mutations	O
in	O
30	O
kindreds	O
,	O
including	O
15	O
not	O
previously	O
reported	O
.	O

GM1	B-Disease
-	I-Disease
gangliosidosis	I-Disease
is	O
a	O
lysosomal	B-Disease
storage	I-Disease
disorder	I-Disease
caused	O
by	O
deficiency	B-Disease
of	I-Disease
acid	I-Disease
beta	I-Disease
-	I-Disease
galactosidase	I-Disease
(	O
GLB1	O
)	O
.	O

Interestingly	O
,	O
all	O
patients	O
with	O
cardiac	B-Disease
involvement	I-Disease
were	O
homozygous	O
for	O
one	O
of	O
these	O
mutations	O
R59H	O
,	O
Y591C	O
,	O
Y591N	O
,	O
or	O
IVS14	O
-	O
2A	O
>	O
G	O
.	O

In	O
vivo	O
modulation	O
of	O
Hmgic	O
reduces	O
obesity	B-Disease
.	O

To	O
study	O
its	O
role	O
in	O
adipogenesis	O
and	O
obesity	B-Disease
,	O
we	O
examined	O
Hmgic	O
expression	O
in	O
the	O
adipose	O
tissue	O
of	O
adult	O
,	O
obese	B-Disease
mice	O
.	O

Disruption	O
of	O
Hmgic	O
caused	O
a	O
reduction	O
in	O
the	O
obesity	B-Disease
induced	O
by	O
leptin	B-Disease
deficiency	I-Disease
(	O
Lepob	O
/	O
Lepob	O
)	O
in	O
a	O
gene	O
-	O
dose	O
-	O
dependent	O
manner	O
.	O

Molecular	O
analysis	O
of	O
the	O
genotype	O
-	O
phenotype	O
relationship	O
in	O
factor	B-Disease
X	I-Disease
deficiency	I-Disease
.	O

The	O
factor	O
X	O
(	O
F10	O
)	O
genes	O
of	O
14	O
unrelated	O
individuals	O
with	O
factor	B-Disease
X	I-Disease
deficiency	I-Disease
(	O
12	O
familial	O
and	O
two	O
sporadic	O
cases	O
)	O
were	O
sequenced	O
yielding	O
a	O
total	O
of	O
13	O
novel	O
mutations	O
.	O

Chromosomal	O
translocations	O
in	O
human	O
lipomas	B-Disease
frequently	O
create	O
fusion	O
transcripts	O
encoding	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
I	O
-	O
C	O
DNA	O
-	O
binding	O
domains	O
and	O
C	O
-	O
terminal	O
sequences	O
from	O
different	O
presumed	O
transcription	O
factors	O
,	O
suggesting	O
a	O
potential	O
role	O
for	O
HMG	O
I	O
-	O
C	O
in	O
the	O
development	O
of	O
lipomas	B-Disease
.	O

These	O
findings	O
demonstrate	O
that	O
the	O
DNA	O
-	O
binding	O
domains	O
of	O
HMG	O
I	O
-	O
C	O
,	O
in	O
the	O
absence	O
of	O
a	O
C	O
-	O
terminal	O
fusion	O
partner	O
,	O
are	O
sufficient	O
to	O
perturb	O
adipogenesis	O
and	O
predispose	O
to	O
lipomas	B-Disease
.	O

The	O
rare	B-Disease
diseases	I-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
AT	B-Disease
)	O
,	O
caused	O
by	O
mutations	O
in	O
the	O
ATM	O
gene	O
,	O
and	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
(	O
NBS	B-Disease
)	O
,	O
with	O
mutations	O
in	O
the	O
p95	O
/	O
nbs1	O
gene	O
,	O
share	O
a	O
variety	O
of	O
phenotypic	B-Disease
abnormalities	I-Disease
such	O
as	O
chromosomal	B-Disease
instability	I-Disease
,	O
radiation	O
sensitivity	O
and	O
defects	O
in	O
cell	O
-	O
cycle	O
checkpoints	O
in	O
response	O
to	O
ionizing	O
radiation	O
.	O

Activation	O
of	O
the	O
ATM	O
kinase	O
by	O
ionizing	O
radiation	O
and	O
induction	O
of	O
ATM	O
-	O
dependent	O
responses	O
in	O
NBS	B-Disease
cells	O
indicated	O
that	O
p95	O
/	O
nbs1	O
may	O
not	O
be	O
required	O
for	O
signalling	O
to	O
ATM	O
after	O
ionizing	O
radiation	O
.	O

Understanding	O
the	O
molecular	O
basis	O
of	O
fragile	B-Disease
X	I-Disease
syndrome	I-Disease
.	O

In	O
patients	O
with	O
fragile	B-Disease
X	I-Disease
syndrome	I-Disease
,	O
the	O
expanded	O
CGG	O
triplet	O
repeats	O
are	O
hypermethylated	O
and	O
the	O
expression	O
of	O
the	O
FMR1	O
gene	O
is	O
repressed	O
,	O
which	O
leads	O
to	O
the	O
absence	O
of	O
FMR1	O
protein	O
(	O
FMRP	O
)	O
and	O
subsequent	O
mental	B-Disease
retardation	I-Disease
.	O

Anterior	B-Disease
segment	I-Disease
developmental	I-Disease
disorders	I-Disease
,	O
including	O
Axenfeld	B-Disease
-	I-Disease
Rieger	I-Disease
anomaly	I-Disease
(	O
ARA	B-Disease
)	O
,	O
variably	O
associate	O
with	O
harmfully	O
elevated	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
,	O
which	O
causes	O
glaucoma	B-Disease
.	O

Mutations	O
in	O
the	O
human	O
homolog	O
of	O
Foxc1	O
,	O
FKHL7	O
,	O
cause	O
dominant	O
anterior	B-Disease
segment	I-Disease
defects	I-Disease
and	O
glaucoma	B-Disease
in	O
various	O
families	O
.	O

These	O
abnormalities	O
include	O
small	O
or	O
absent	O
Schlemms	O
canal	O
,	O
aberrantly	O
developed	O
trabecular	O
meshwork	O
,	O
iris	B-Disease
hypoplasia	I-Disease
,	O
severely	O
eccentric	O
pupils	O
and	O
displaced	O
Schwalbes	O
line	O
.	O

Foxc1	O
(	O
+	O
/	O
-	O
)	O
and	O
Foxc2	O
(	O
+	O
/	O
-	O
)	O
mice	O
are	O
useful	O
models	O
for	O
studying	O
anterior	O
segment	O
development	O
and	O
its	O
anomalies	O
,	O
and	O
may	O
allow	O
identification	O
of	O
genes	O
that	O
interact	O
with	O
Foxc1	O
and	O
Foxc2	O
(	O
or	O
FKHL7	O
and	O
FKHL14	O
)	O
to	O
produce	O
a	O
phenotype	O
with	O
elevated	O
IOP	O
and	O
glaucoma	B-Disease
.	O
.	O

Fragile	B-Disease
X	I-Disease
syndrome	I-Disease
is	O
a	O
common	O
cause	O
of	O
mental	B-Disease
retardation	I-Disease
involving	O
loss	O
of	O
expression	O
of	O
the	O
FMR1	O
gene	O
.	O

As	O
a	O
step	O
toward	O
understanding	O
the	O
function	O
of	O
FMR1	O
and	O
the	O
determination	O
of	O
the	O
potential	O
for	O
therapeutic	O
approaches	O
to	O
fragile	B-Disease
X	I-Disease
syndrome	I-Disease
,	O
yeast	O
artificial	O
chromosome	O
(	O
YAC	O
)	O
transgenic	O
mice	O
were	O
generated	O
in	O
order	O
to	O
determine	O
whether	O
the	O
Fmr1	O
knockout	O
mouse	O
phenotype	O
could	O
be	O
rescued	O
.	O

The	O
mouse	O
displayed	O
reduced	O
anxiety	B-Disease
-	O
related	O
responses	O
with	O
increased	O
exploratory	O
behavior	O
.	O

Transgenic	O
mice	O
carrying	O
large	O
human	O
genomic	O
sequences	O
with	O
expanded	O
CTG	O
repeat	O
mimic	O
closely	O
the	O
DM	B-Disease
CTG	O
repeat	O
intergenerational	O
and	O
somatic	O
instability	O
.	O

Furthermore	O
,	O
tissues	O
from	O
DM	B-Disease
patients	O
exhibit	O
somatic	O
mosaicism	O
that	O
increases	O
with	O
age	O
.	O

Although	O
we	O
did	O
not	O
observe	O
dramatic	O
expansions	O
(	O
or	O
big	O
jumps	O
over	O
several	O
hundred	O
CTG	O
repeats	O
)	O
as	O
in	O
congenital	O
forms	O
of	O
DM	B-Disease
,	O
our	O
model	O
carrying	O
>	O
300	O
CTG	O
is	O
the	O
first	O
to	O
show	O
instability	O
so	O
close	O
to	O
the	O
human	O
DM	B-Disease
situation	O
.	O

Friedreich	B-Disease
ataxia	I-Disease
(	O
FRDA	B-Disease
)	O
,	O
the	O
most	O
common	O
autosomal	B-Disease
recessive	I-Disease
ataxia	I-Disease
,	O
is	O
caused	O
in	O
almost	O
all	O
cases	O
by	O
homozygous	O
intronic	O
expansions	O
resulting	O
in	O
the	O
loss	O
of	O
frataxin	O
,	O
a	O
mitochondrial	O
protein	O
conserved	O
through	O
evolution	O
,	O
and	O
involved	O
in	O
mitochondrial	O
iron	O
homeostasis	O
.	O

To	O
study	O
the	O
mechanism	O
of	O
the	O
disease	O
,	O
we	O
generated	O
a	O
mouse	O
model	O
by	O
deletion	O
of	O
exon	O
4	O
leading	O
to	O
inactivation	O
of	O
the	O
Frda	B-Disease
gene	O
product	O
.	O

Gaucher	B-Disease
disease	I-Disease
:	O
the	O
origins	O
of	O
the	O
Ashkenazi	O
Jewish	O
N370S	O
and	O
84GG	O
acid	O
beta	O
-	O
glucosidase	O
mutations	O
.	O

HLA	O
B27	O
and	O
the	O
genetics	O
of	O
ankylosing	B-Disease
spondylitis	I-Disease
.	O

Five	O
patients	O
had	O
evidence	O
of	O
a	O
sero	O
-	O
negative	O
peripheral	B-Disease
arthritis	I-Disease
resembling	O
peripheral	B-Disease
psoriatic	I-Disease
arthritis	I-Disease
and	O
3	O
of	O
these	O
were	O
B27	O
negative	O
.	O

These	O
findings	O
are	O
interpreted	O
as	O
suggesting	O
some	O
degree	O
of	O
clinical	O
and	O
genetic	O
heterogeneity	O
in	O
ankylosing	B-Disease
spondylitis	I-Disease
with	O
genes	O
for	O
psoriasis	B-Disease
and	O
inflammatory	B-Disease
bowel	I-Disease
disease	I-Disease
being	O
important	O
in	O
some	O
individuals	O
,	O
particularly	O
those	O
who	O
are	O
B27	O
negative	O
.	O

The	O
only	O
instance	O
of	O
disassociation	O
of	O
B27	O
and	O
spondylitis	B-Disease
in	O
a	O
family	O
was	O
where	O
the	O
proband	O
had	O
ulcerative	B-Disease
colitis	I-Disease
as	O
well	O
as	O
spondylitis	B-Disease
.	O

These	O
findings	O
are	O
thought	O
to	O
provide	O
evidence	O
against	O
the	O
concept	O
that	O
the	O
gene	O
for	O
ankylosing	B-Disease
spondylitis	I-Disease
is	O
not	O
B27	O
but	O
a	O
closely	O
linked	O
gene	O
and	O
favour	O
the	O
occurrence	O
of	O
an	O
environmental	O
event	O
affecting	O
approximately	O
one	O
-	O
fifth	O
of	O
B27	O
positive	O
males	O
to	O
result	O
in	O
disease	O
.	O
.	O

The	O
study	O
group	O
consisted	O
of	O
66	O
Polish	O
families	O
with	O
cancer	B-Disease
who	O
have	O
at	O
least	O
three	O
related	O
females	O
affected	O
with	O
breast	B-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
and	O
who	O
had	O
cancer	B-Disease
diagnosed	O
,	O
in	O
at	O
least	O
one	O
of	O
the	O
three	O
affected	O
females	O
,	O
at	O
age	O
<	O
50	O
years	O
.	O

BRCA1	B-Disease
abnormalities	I-Disease
were	O
identified	O
in	O
all	O
four	O
families	O
with	O
ovarian	B-Disease
cancer	I-Disease
only	O
,	O
in	O
67	O
%	O
of	O
27	O
families	O
with	O
both	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
,	O
and	O
in	O
34	O
%	O
of	O
35	O
families	O
with	O
breast	B-Disease
cancer	I-Disease
only	O
.	O

Three	O
BRCA1	B-Disease
abnormalities	I-Disease
-	O
5382insC	O
,	O
C61G	O
,	O
and	O
4153delA	O
-	O
accounted	O
for	O
51	O
%	O
,	O
20	O
%	O
,	O
and	O
11	O
%	O
of	O
the	O
identified	O
mutations	O
,	O
respectively	O
.	O
.	O

Very	B-Disease
long	I-Disease
chain	I-Disease
acyl	I-Disease
-	I-Disease
CoA	I-Disease
dehydrogenase	I-Disease
(	I-Disease
VLCAD	I-Disease
)	I-Disease
deficiency	I-Disease
is	O
a	O
life	O
-	O
threatening	O
disorder	O
of	O
mitochondrial	O
fatty	O
acid	O
beta	O
-	O
oxidation	O
.	O

Submicroscopic	O
deletion	O
in	O
cousins	O
with	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
causes	O
a	O
grandmatrilineal	O
inheritance	O
pattern	O
:	O
effects	O
of	O
imprinting	O
.	O

PWS	B-Disease
becomes	O
apparent	O
when	O
genes	O
on	O
the	O
paternally	O
inherited	O
chromosome	O
are	O
not	O
expressed	O
.	O

We	O
report	O
on	O
a	O
family	O
in	O
which	O
a	O
male	O
and	O
a	O
female	O
paternal	O
first	O
cousin	O
both	O
have	O
PWS	B-Disease
with	O
cytogenetically	O
normal	O
karyotypes	O
.	O

In	O
this	O
case	O
,	O
PWS	B-Disease
does	O
not	O
become	O
evident	O
as	O
long	O
as	O
the	O
deletion	O
is	O
passed	O
through	O
the	O
matrilineal	O
line	O
.	O

Mutations	O
in	O
the	O
glycine	O
decarboxylase	O
gene	O
(	O
GLDC	O
)	O
cause	O
nonketotic	B-Disease
hyperglycinemia	I-Disease
(	O
NKH	B-Disease
)	O
,	O
an	O
in	B-Disease
-	I-Disease
born	I-Disease
error	I-Disease
of	I-Disease
metabolism	I-Disease
characterized	O
by	O
severe	O
neurological	B-Disease
disturbance	I-Disease
.	O

We	O
have	O
also	O
examined	O
a	O
patient	O
with	O
NKH	B-Disease
with	O
no	O
detectable	O
GLDC	O
mRNA	O
in	O
his	O
lymphoblasts	O
.	O

Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
is	O
a	O
neurogenetic	B-Disease
disease	I-Disease
characterized	O
by	O
infantile	B-Disease
hypotonia	I-Disease
,	O
gonadal	B-Disease
hypoplasia	I-Disease
,	O
obsessive	O
behaviour	O
and	O
neonatal	O
feeding	O
difficulties	O
followed	O
by	O
hyperphagia	B-Disease
,	O
leading	O
to	O
profound	O
obesity	B-Disease
.	O

Five	O
imprinted	O
,	O
paternally	O
expressed	O
genes	O
map	O
to	O
the	O
PWS	B-Disease
region	O
,	O
MKRN3	O
(	O
ref	O
.	O
3	O
)	O
,	O
NDN	O
(	O
ref	O
.	O
4	O
)	O
,	O
NDNL1	O
(	O
ref	O
.	O
5	O
)	O
,	O
SNRPN	O
(	O
refs	O
6	O
-	O
8	O
)	O
and	O
IPW	O
(	O
ref	O
.	O
9	O
)	O
,	O
as	O
well	O
as	O
two	O
poorly	O
characterized	O
framents	O
designated	O
PAR	O
-	O
1	O
and	O
PAR	O
-	O
5	O
(	O
ref	O
.	O
10	O
)	O
.	O

Here	O
we	O
report	O
a	O
PWS	B-Disease
family	O
in	O
which	O
the	O
father	O
is	O
mosaic	O
for	O
an	O
IC	O
deletion	O
on	O
his	O
paternal	O
chromosome	O
.	O

Mice	O
deficient	B-Disease
in	I-Disease
Six5	I-Disease
develop	O
cataracts	B-Disease
:	O
implications	O
for	O
myotonic	B-Disease
dystrophy	I-Disease
.	O

Targeted	O
deletion	O
of	O
Dm15	O
,	O
the	O
mouse	O
orthologue	O
of	O
human	O
DMPK	O
,	O
produced	O
mice	O
with	O
a	O
mild	O
myopathy	B-Disease
and	O
cardiac	B-Disease
conduction	I-Disease
abnormalities	I-Disease
,	O
but	O
without	O
other	O
features	O
of	O
myotonic	B-Disease
dystrophy	I-Disease
,	O
such	O
as	O
myotonia	B-Disease
and	O
cataracts	B-Disease
.	O

Homozygous	O
mutant	O
mice	O
had	O
no	O
apparent	O
abnormalities	B-Disease
of	I-Disease
skeletal	I-Disease
muscle	I-Disease
function	I-Disease
,	O
but	O
developed	O
lenticular	B-Disease
opacities	I-Disease
at	O
a	O
higher	O
rate	O
than	O
controls	O
.	O

Heterozygous	O
loss	O
of	O
Six5	O
in	O
mice	O
is	O
sufficient	O
to	O
cause	O
ocular	O
cataracts	B-Disease
.	O

The	O
genetic	B-Disease
defect	I-Disease
in	O
DM	B-Disease
is	O
a	O
CTG	O
repeat	O
expansion	O
located	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
DMPK	O
and	O
5	O
of	O
a	O
homeodomain	O
-	O
encoding	O
gene	O
,	O
SIX5	O
(	O
formerly	O
DMAHP	O
;	O
refs	O
2	O
-	O
5	O
)	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
a	O
dose	O
-	O
dependent	O
loss	O
of	O
Dm15	O
(	O
the	O
mouse	O
DMPK	O
homologue	O
)	O
in	O
mice	O
produces	O
a	O
partial	O
DM	B-Disease
phenotype	O
characterized	O
by	O
decreased	O
development	O
of	O
skeletal	O
muscle	O
force	O
and	O
cardiac	B-Disease
conduction	I-Disease
disorders	I-Disease
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
rate	O
and	O
severity	O
of	O
cataract	B-Disease
formation	O
is	O
inversely	O
related	O
to	O
Six5	O
dosage	O
and	O
is	O
temporally	O
progressive	O
.	O

As	O
ocular	O
cataracts	B-Disease
are	O
a	O
characteristic	O
feature	O
of	O
DM	B-Disease
,	O
these	O
results	O
demonstrate	O
that	O
decreased	O
SIX5	O
transcription	O
is	O
important	O
in	O
the	O
aetiology	O
of	O
DM	B-Disease
.	O

Mutations	O
in	O
the	O
gene	O
ATM	O
are	O
responsible	O
for	O
the	O
genetic	B-Disease
disorder	I-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
A	B-Disease
-	I-Disease
T	I-Disease
)	O
,	O
which	O
is	O
characterized	O
by	O
cerebellar	B-Disease
dysfunction	I-Disease
,	O
radiosensitivity	O
,	O
chromosomal	O
instability	O
and	O
cancer	B-Disease
predisposition	O
.	O

There	O
are	O
strong	O
parallels	O
between	O
the	O
pattern	O
of	O
radiosensitivity	O
,	O
chromosomal	O
instability	O
and	O
cancer	B-Disease
predisposition	O
in	O
A	B-Disease
-	I-Disease
T	I-Disease
patients	O
and	O
that	O
in	O
patients	O
with	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
(	O
NBS	B-Disease
)	O
.	O

The	O
overlap	O
between	O
clinical	O
and	O
cellular	O
phenotypes	O
in	O
A	B-Disease
-	I-Disease
T	I-Disease
and	O
NBS	B-Disease
suggests	O
that	O
ATM	O
and	O
nibrin	O
may	O
function	O
in	O
the	O
same	O
biochemical	O
pathway	O
.	O

Phosphorylation	O
of	O
this	O
site	O
appears	O
to	O
be	O
functionally	O
important	O
because	O
mutated	O
nibrin	O
(	O
S343A	O
)	O
does	O
not	O
completely	O
complement	O
radiosensitivity	O
in	O
NBS	B-Disease
cells	O
.	O

Clinicopathologic	O
features	O
of	O
BRCA	B-Disease
-	I-Disease
linked	I-Disease
and	I-Disease
sporadic	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O

Attempts	O
to	O
define	O
the	O
clinical	O
significance	O
of	O
BRCA	O
mutation	O
status	O
in	O
ovarian	B-Disease
cancer	I-Disease
have	O
produced	O
conflicting	O
results	O
,	O
especially	O
regarding	O
survival	O
.	O

DESIGN	O
AND	O
SETTING	O
Retrospective	O
cohort	O
study	O
of	O
a	O
consecutive	O
series	O
of	O
933	O
ovarian	B-Disease
cancers	I-Disease
diagnosed	O
and	O
treated	O
at	O
our	O
institution	O
,	O
which	O
is	O
a	O
comprehensive	O
cancer	B-Disease
center	O
as	O
designated	O
by	O
the	O
National	O
Cancer	B-Disease
Institute	O
,	O
over	O
a	O
12	O
-	O
year	O
period	O
(	O
December	O
1986	O
to	O
August	O
1998	O
)	O
.	O

RESULTS	O
Hereditary	B-Disease
cancers	I-Disease
were	O
rarely	O
diagnosed	O
before	O
age	O
40	O
years	O
and	O
were	O
common	O
after	O
age	O
60	O
years	O
,	O
with	O
mean	O
age	O
at	O
diagnosis	O
being	O
significantly	O
younger	O
for	O
BRCA1	O
-	O
vs	O
BRCA2	O
-	O
linked	O
patients	O
(	O
54	O
vs	O
62	O
years	O
;	O
P	O
=	O
.	O
04	O
)	O
.	O

For	O
stage	B-Disease
III	I-Disease
cancers	I-Disease
,	O
BRCA	O
mutation	O
status	O
was	O
an	O
independent	O
prognostic	O
variable	O
(	O
P	O
=	O
.	O
03	O
)	O
.	O

Age	O
penetrance	O
is	O
greater	O
for	O
BRCA1	B-Disease
-	I-Disease
linked	I-Disease
than	I-Disease
for	I-Disease
BRCA2	I-Disease
-	I-Disease
linked	I-Disease
cancers	I-Disease
in	O
this	O
population	O
.	O

Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	B-Disease
)	O
is	O
a	O
recessive	B-Disease
disorder	I-Disease
characterized	O
by	O
episodes	O
of	O
fever	B-Disease
and	O
neutrophil	B-Disease
-	I-Disease
mediated	I-Disease
serosal	I-Disease
inflammation	I-Disease
.	O

In	O
vitro	O
stimulation	O
of	O
monocytes	O
with	O
the	O
proinflammatory	O
agents	O
interferon	O
(	O
IFN	O
)	O
gamma	O
,	O
tumor	B-Disease
necrosis	O
factor	O
,	O
and	O
lipopolysaccharide	O
induced	O
MEFV	O
expression	O
,	O
whereas	O
the	O
antiinflammatory	O
cytokines	O
interleukin	O
(	O
IL	O
)	O
4	O
,	O
IL	O
-	O
10	O
,	O
and	O
transforming	O
growth	O
factor	O
beta	O
inhibited	O
such	O
expression	O
.	O

Mucopolysaccharidosis	B-Disease
IVA	I-Disease
(	O
MPS	B-Disease
IVA	I-Disease
;	O
OMIM	O
#	O
253000	O
)	O
,	O
a	O
lysosomal	B-Disease
storage	I-Disease
disorder	I-Disease
caused	O
by	O
a	O
deficiency	B-Disease
of	I-Disease
N	I-Disease
-	I-Disease
acetylgalactosamine	I-Disease
-	I-Disease
6	I-Disease
-	I-Disease
sulfate	I-Disease
sulfatase	I-Disease
(	O
GALNS	O
)	O
,	O
has	O
variable	O
clinical	O
phenotypes	O
.	O

These	O
studies	O
shed	O
further	O
light	O
on	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
of	O
MPS	B-Disease
IVA	I-Disease
and	O
structure	O
-	O
function	O
relationship	O
in	O
the	O
sulfatase	O
family	O
.	O

Mutations	O
at	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
A	B-Disease
-	I-Disease
T	I-Disease
)	O
locus	O
on	O
chromosome	O
band	O
11q22	O
cause	O
a	O
distinctive	O
autosomal	B-Disease
recessive	I-Disease
syndrome	I-Disease
in	O
homozygotes	O
and	O
predispose	O
heterozygotes	O
to	O
cancer	B-Disease
,	O
ischemic	B-Disease
heart	I-Disease
disease	I-Disease
,	O
and	O
early	O
mortality	O
.	O

Heteroduplex	O
analysis	O
detected	O
another	O
42	O
mutations	O
at	O
the	O
A	B-Disease
-	I-Disease
T	I-Disease
locus	O
.	O

The	O
mean	O
survival	O
and	O
height	O
distribution	O
of	O
134	O
A	B-Disease
-	I-Disease
T	I-Disease
patients	O
correlated	O
significantly	O
with	O
the	O
specific	O
mutations	O
present	O
in	O
the	O
patients	O
.	O

Mutation	O
analysis	O
at	O
the	O
A	B-Disease
-	I-Disease
T	I-Disease
locus	O
may	O
help	O
estimate	O
the	O
prognosis	O
of	O
A	B-Disease
-	I-Disease
T	I-Disease
patients	O
.	O
.	O

Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	B-Disease
)	O
is	O
a	O
recessive	B-Disease
disorder	I-Disease
characterized	O
by	O
episodes	O
of	O
fever	B-Disease
with	O
serositis	B-Disease
or	O
synovitis	B-Disease
.	O

2	O
domain	O
,	O
in	O
which	O
most	O
FMF	B-Disease
-	O
associated	O
mutations	O
have	O
been	O
found	O
in	O
human	O
MEFV	O
.	O

Mutations	O
and	O
duplications	O
of	O
this	O
gene	O
are	O
associated	O
with	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
(	O
PMD	B-Disease
)	O
.	O

In	O
a	O
second	O
unrelated	O
family	O
with	O
signs	O
of	O
PMD	B-Disease
,	O
cytogenetic	O
analysis	O
showed	O
a	O
pericentric	O
inversion	O
of	O
the	O
X	O
chromosome	O
.	O

To	O
do	O
this	O
,	O
a	O
collaborative	O
screening	O
study	O
was	O
set	O
up	O
that	O
involved	O
39	O
institutions	O
from	O
19	O
countries	O
and	O
included	O
3	O
,	O
580	O
unrelated	O
individuals	O
with	O
a	O
family	O
history	O
of	O
the	O
disease	O
and	O
934	O
early	O
-	O
onset	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
cases	O
.	O

Von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	I-Disease
(	I-Disease
VHL	I-Disease
)	I-Disease
disease	I-Disease
is	O
a	O
hereditary	B-Disease
tumor	I-Disease
syndrome	I-Disease
characterized	O
by	O
predisposition	O
for	O
bilateral	B-Disease
and	I-Disease
multi	I-Disease
-	I-Disease
centric	I-Disease
hemangioblastoma	I-Disease
in	O
the	O
retina	O
and	O
central	O
nervous	O
system	O
,	O
pheochromocytoma	B-Disease
,	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
,	O
and	O
cysts	B-Disease
in	I-Disease
the	I-Disease
kidney	I-Disease
,	I-Disease
pancreas	I-Disease
,	I-Disease
and	I-Disease
epididymis	I-Disease
.	O

Further	O
molecular	O
analysis	O
revealed	O
deletions	O
involving	O
the	O
VHL	B-Disease
gene	O
in	O
each	O
of	O
these	O
families	O
.	O

Our	O
results	O
show	O
that	O
(	O
quantitative	O
)	O
Southern	O
blot	O
analysis	O
is	O
a	O
sensitive	O
method	O
for	O
detecting	O
germline	O
deletions	O
of	O
the	O
VHL	B-Disease
gene	O
and	O
should	O
be	O
implemented	O
in	O
routine	O
DNA	O
diagnosis	O
for	O
VHL	B-Disease
disease	I-Disease
.	O

Further	O
unraveling	O
of	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
VHL	B-Disease
disease	I-Disease
has	O
revealed	O
that	O
families	O
with	O
a	O
full	O
or	O
partial	O
deletion	O
of	O
the	O
VHL	B-Disease
gene	O
exhibit	O
a	O
phenotype	O
with	O
a	O
preponderance	O
of	O
central	B-Disease
nervous	I-Disease
system	I-Disease
hemangioblastoma	I-Disease
.	O
.	O

Friedreich	B-Disease
ataxia	I-Disease
(	O
FRDA	B-Disease
)	O
,	O
the	O
most	O
frequently	O
inherited	B-Disease
ataxia	I-Disease
,	O
is	O
due	O
in	O
the	O
vast	O
majority	O
of	O
cases	O
to	O
a	O
large	O
expansion	O
of	O
an	O
intronic	O
GAA	O
repeat	O
.	O

Functional	O
link	O
between	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
and	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
gene	O
products	O
.	O

The	O
protein	O
product	O
of	O
the	O
gene	O
responsible	O
for	O
A	B-Disease
-	I-Disease
T	I-Disease
,	O
designated	O
ATM	O
,	O
is	O
a	O
member	O
of	O
a	O
family	O
of	O
kinases	O
characterized	O
by	O
a	O
carboxy	O
-	O
terminal	O
phosphatidylinositol	O
3	O
-	O
kinase	O
-	O
like	O
domain	O
.	O

This	O
response	O
includes	O
S	O
-	O
phase	O
checkpoint	O
activation	O
,	O
formation	O
of	O
the	O
NBS1	O
/	O
Mrel1	O
/	O
Rad50	O
nuclear	O
foci	O
and	O
rescue	O
of	O
hypersensitivity	B-Disease
to	I-Disease
ionizing	I-Disease
radiation	I-Disease
.	O

Homozygosity	O
mapping	O
in	O
a	O
family	O
with	O
microcephaly	B-Disease
,	O
mental	B-Disease
retardation	I-Disease
,	O
and	O
short	B-Disease
stature	I-Disease
to	O
a	O
Cohen	B-Disease
syndrome	I-Disease
region	O
on	O
8q21	O
.	O
3	O
-	O
8q22	O
.	O
1	O
:	O
redefining	O
a	O
clinical	O
entity	O
.	O

Hypotonia	B-Disease
,	O
chorioretinal	B-Disease
dystrophy	I-Disease
,	O
and	O
myopia	B-Disease
were	O
also	O
identified	O
.	O

Intriguingly	O
enough	O
,	O
the	O
identified	O
gene	O
region	O
overlaps	O
the	O
refined	O
gene	O
region	O
for	O
Cohen	B-Disease
syndrome	I-Disease
(	O
COH1	O
)	O
[	O
Kolehmainen	O
et	O
al	O
.	O
,	O
1997	O
Euro	O
J	O
Hum	O
Genet	O
5	O
206	O
-	O
213	O
]	O
.	O

Polymorphisms	O
of	O
the	O
CYP2D6	O
gene	O
increase	O
susceptibility	O
to	O
ankylosing	B-Disease
spondylitis	I-Disease
.	O

Previous	O
linkage	O
and	O
association	O
studies	O
have	O
suggested	O
the	O
presence	O
of	O
a	O
susceptibility	O
gene	O
for	O
AS	B-Disease
close	O
to	O
,	O
or	O
within	O
,	O
the	O
cytochrome	O
P450	O
2D6	O
gene	O
(	O
CYP2D6	O
,	O
debrisoquine	O
hydroxylase	O
)	O
located	O
at	O
chromosome	O
22q13	O
.	O
1	O
.	O

For	O
case	O
-	O
control	O
studies	O
,	O
617	O
unrelated	O
individuals	O
with	O
AS	B-Disease
(	O
361	O
probands	O
from	O
sibling	O
-	O
pair	O
and	O
parent	O
-	O
case	O
trio	O
families	O
and	O
256	O
unrelated	O
non	O
-	O
familial	O
sporadic	O
cases	O
)	O
and	O
402	O
healthy	O
ethnically	O
matched	O
controls	O
were	O
employed	O
.	O

Heterozygosity	O
for	O
the	O
most	O
frequent	O
poor	O
metabolizer	O
allele	O
(	O
CYP2D6	O
*	O
4	O
)	O
was	O
not	O
associated	O
with	O
increased	O
susceptibility	O
to	O
AS	B-Disease
.	O

Weak	O
linkage	O
was	O
also	O
demonstrated	O
between	O
CYP2D6	O
and	O
AS	B-Disease
.	O

Functional	O
differences	O
of	O
the	O
PDS	B-Disease
gene	O
product	O
are	O
associated	O
with	O
phenotypic	O
variation	O
in	O
patients	O
with	O
Pendred	B-Disease
syndrome	I-Disease
and	O
non	B-Disease
-	I-Disease
syndromic	I-Disease
hearing	I-Disease
loss	I-Disease
(	O
DFNB4	B-Disease
)	O
.	O

Mutations	O
in	O
this	O
gene	O
are	O
responsible	O
for	O
Pendred	B-Disease
syndrome	I-Disease
and	O
autosomal	B-Disease
recessive	I-Disease
non	I-Disease
-	I-Disease
syndromic	I-Disease
hearing	I-Disease
loss	I-Disease
at	O
the	O
DFNB4	B-Disease
locus	O
on	O
chromosome	O
7q31	O
.	O

To	O
determine	O
whether	O
PDS	B-Disease
mutations	O
in	O
individuals	O
with	O
Pendred	B-Disease
syndrome	I-Disease
differ	O
functionally	O
from	O
PDS	B-Disease
mutations	O
in	O
individuals	O
with	O
non	B-Disease
-	I-Disease
syndromic	I-Disease
hearing	I-Disease
loss	I-Disease
,	O
we	O
compared	O
three	O
common	O
Pendred	B-Disease
syndrome	I-Disease
allele	O
variants	O
(	O
L236P	O
,	O
T416P	O
and	O
E384G	O
)	O
,	O
with	O
three	O
PDS	B-Disease
mutations	O
reported	O
only	O
in	O
individuals	O
with	O
non	B-Disease
-	I-Disease
syndromic	I-Disease
hearing	I-Disease
loss	I-Disease
(	O
V480D	O
,	O
V653A	O
and	O
I490L	O
/	O
G497S	O
)	O
.	O

We	O
hypothesize	O
that	O
this	O
residual	O
level	O
of	O
anion	O
transport	O
is	O
sufficient	O
to	O
eliminate	O
or	O
postpone	O
the	O
onset	O
of	O
goiter	B-Disease
in	O
individuals	O
with	O
DFNB4	B-Disease
.	O

Here	O
,	O
we	O
compare	O
the	O
pattern	O
of	O
germline	O
mutation	O
in	O
a	O
population	O
of	O
hemophilia	B-Disease
B	I-Disease
patients	O
from	O
Mainland	O
China	O
(	O
n	O
=	O
66	O
)	O
to	O
that	O
in	O
U	O
.	O

